Biomarkers of immune dysfunction in response to chronic stress, methods of use and diagnostic kits

Information

  • Patent Grant
  • 11618922
  • Patent Number
    11,618,922
  • Date Filed
    Monday, October 20, 2014
    11 years ago
  • Date Issued
    Tuesday, April 4, 2023
    2 years ago
Abstract
Diagnostic biomarkers for diagnosing immune suppression/dysfunction. The diagnostic biomarkers are genes and/or transcripts that are up or down regulated compared to normal expression when a subject has been stressed either mentally and/or physically. The invention also relates to a method of detecting comprised or suppressed immune response in a subject by comparing certain diagnostic biomarkers in the subject to a control set of diagnostic biomarkers.
Description
BACKGROUND OF THE INVENTION
1 Field of the Invention

The present invention relates to diagnostic biomarkers of immune suppression/dysfunction. The diagnostic biomarkers may be used to evaluate the capability of immune cells in subjects, and screen subjects for immune suppression/dysfunction in response to stress and/or pathogen exposure.


The present invention further relates to diagnostic biomarkers suitable for diagnosing Staphylococcus Enterotoxin B (SEB) exposure in a subject, and methods of using the same. These diagnostic biomarkers are suitable for diagnosing SEB exposure in the presence of comprised immune response or stress.


SUMMARY OF THE INVENTION

Diagnostic biomarkers for diagnosing immune suppression/dysfunction. The diagnostic biomarkers are transcripts that are up or down regulated compared to normal expression when a subject has been stressed either mentally and/or physically. The invention also relates to a method of detecting comprised or suppressed immune response in a subject by comparing certain diagnostic biomarkers in the subject to a control set of diagnostic biomarkers.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1A is a graph showing comparisons of before and after training of weights, temperatures and blood pressures of cadets;



FIG. 1B) is a graph showing differential and complete leukocyte counts of trainees before and after training including complete and differential blood counts for pre- and post-Training subjects that include red blood cells, white blood cells, neutrophils and lymphocytes; monocytes, eosophils and basophils;



FIG. 1C is a graph showing differential and complete leukocyte counts of trainees before and after training that include complete and differential blood counts for pre- and post-Training subjects included monocytes, eosophils and basophils;



FIG. 2A is a table showing the analysis of differentially expressed genes in leukocytes of Ranger Trainees before and after Training;



FIG. 2B is a heat map that shows Hierarchical clustering of 288 genes that passed Welch's t-test with FDR correction (q<0.001) and had expression alteration of ≥1.5 fold with each lane showing the 288 genes and their leukocyte expression level for each subject before (left panel) or after (right panel) training in comparison to human universal RNA;



FIGS. 3A-E are graphs showing correlation of real time PCR arrays with those from cDNA and oligonucleotide microarrays;



FIG. 4A is a graph showing correlation of Real time QPCR and cDNA microarray analyses;



FIG. 4B) is a graph showing ELISA determination of plasma concentrations of proteins, and comparison with level of their transcripts from microarrays data;



FIG. 5A is a heat map of expression patterns of immune response genes in leukocytes in-vitro exposed to SEB;



FIG. 5B is a heat map of predicted and experimentally observed targets of RASP-regulated microRNAs;



FIG. 5C is a sample PCA of differentially regulated microRNAs that passed Welch's Test (p<0.25) and 1.3 fold change cut off;



FIG. 5D is a map of regulatory interaction among stress-induced miRs, important transcription factors (NFkB1, NR3Ca, SATB1), inflammatory cytokines and antigen presenting molecules;



FIG. 5E is a map showing seven stress-suppressed miRs targeting 48 mRNAs among differentially regulated mRNAs that passed q<0.001 and 1.5 fold change;



FIG. 6 is a graph showing predicted targets of miR-155 and let-7f families;



FIG. 7A is a map of transcription factors predicted to be inhibited by battlefield stressors and their targets among stress-affected genes;



FIG. 7B is a map showing transcription factors targeting RT-PCR assayed and differentially regulated genes;



FIG. 8 is a map of functional network of differentially expressed genes connected by their sub-functions in the immune system;



FIG. 9A is a map showing immune response transcripts involved in pattern recognition, viral, antibacterial and effector (humoral) responses;



FIG. 9B is a diagram showing roles of stress down regulated genes in the cellular pathways of immune response;



FIG. 9C is a diagram of action of secreted cytokines on other leukocytes;



FIG. 10A is a diagram showing antigen presentation pathways;



FIG. 10B is a diagram showing expression pattern of genes important for immunological synapse formation;



FIG. 11 is a diagram showing Canonical pathways significantly associated with stress regulated genes that passed Welch's t-test and FDR correction (p<=0.001) and 1.5 fold change;



FIG. 12 is a graph showing relative contribution (rank) of genes in classifying (predicting) control and stress groups of Ranger samples ranked using the Nearest shrunken centroid prediction approach;



FIG. 13A is a graph showing stress specific genes differentiating stress from SEB, dengue virus and Yersinia pestis (plague) infections;



FIG. 13B is also a graph showing stress specific genes differentiating stress from SEB, dengue virus and Yersinia pestis (plague) infections;



FIG. 14 is a graph showing misclassification error rate vs threshold value; and



FIG. 15 is a graph showing cross-validation of the prediction analysis of the invention.





DETAILED DESCRIPTION

Previous studies suggest that excessive or prolonged stress impairs protective immunity towards infection leading to increase susceptibility to illness. Comprehensive molecular explanations of the host's physiological stress response and the results of failed adaptation over time offer the potential to identify the debilitating pathophysiologic consequence of severe stress on health. More importantly, molecular approaches offer the opportunity to implement clinical strategies to differentiate immune impaired individuals from their normal counterparts.


Applicants examined the effects of long-term battlefield-like stressors of U.S. Army Ranger Training on genome wide expression profiles for biomarker identification of prolonged severe, stress-induced, compromised immune response. Applicants identified 59 differentially regulated transcripts using comparative Welch's T-test along with Bonferroni correction (q<0.01) followed by 3-fold change. These 59 differentially regulated transcripts are identified at Table 3 herein. Among the 59 differentially regulated transcripts identified, 48 were down regulated and 11 were up regulated. Most of the down-regulated transcripts were directly involved in protective immunity.


Differentially regulated transcripts identified and their cognate pathways were confirmed using quantitative real-time PCR arrays. Antigen preparation and presentation, chemotaxis, inflammation, and activation of leukocytes were among overrepresented immune response processes that were significantly associated with suppressed transcripts. Differentially regulated transcripts identified or genes from their corresponding pathway can serve as diagnostic biomarkers to differentiate/identify individuals with stress-induced immune suppression. cDNAs of some of these transcripts can be electrochemically tethered in the wells of micro- or nano-chips for quick diagnosis purpose.


Diagnostic biomarkers within the scope of the present invention for use in identifying or screening individuals for immune suppression/dysfunction include five (5) or more, seven (7) or more, or ten (10) or more of the 59 differentially regulated transcripts identified herein or genes from their corresponding pathway. For example purposes, Applicants provide herein a subset of 14 of the 59 transcripts that can be used as a single batch of biomarkers (see Table 3A and 3B). The five (5) or more, seven (7) or more, ten (10) or more or twenty (20) or more of the differentially regulated transcripts or genes from their corresponding pathway may, for example, be selected from these. It is understood to one of ordinary skill in the art that there may be additional biomarkers, not yet identified, that can be used to screen individuals for immune suppression/dysfunction. This invention is not limited to the 59 biomarkers listed in Table 3.


These diagnostic biomarkers would be useful to diagnose immune suppression/dysfunction in a subject due to stress. The present invention further relates to diagnostic kits for use in screening immune function of a subject, where the kit employs the diagnostic biomarkers identified herein.


Applicants further conducted studies on the effect of stress on a patient's ability to respond to other pathogens. More specifically, Applicants studied the effect of Staphylococcus Enterotoxin B (SEB) on host response gene expression profiles, and identified genes that showed consistent differential expression towards SEB whether or not the host had been exposed to stress. These transcripts or genes from their corresponding pathway were SEB-specific (independent of the physiologic and pathologic status of the host), and may serve as diagnostic markers of SEB exposure.


Therefore, this invention proposes a simple test to identify the capability of immune cells to respond to pathogenic agents in military personnel. This biomarker profile would allow for a semi-quantitative method to evaluate the immune system in terms of gene expression.


Transcriptomic Characterization of Immune Suppression from Battlefield-Like Stress


This invention identifies changes in transcriptome of human due to battlefield-like stress. Thorough understanding of stress reactions is likely to produce better strategies to manage stress, and improve health1. Stress modulates gene expression, behavior, metabolism and immune function2-5. Chronic physiological and psychological stresses are major contributors of stress-induced suppression of protective immunity. For example, chronic stress impairs lymphocyte proliferation, vaccination efficacy6-9, NK cell activity, resistance to bacterial and viral infection10, and increases risk of cancer11.


Yet, comprehensive descriptions of molecular responses to stress are needed to fully understand modulated networks and pathways, and hence to reduce and prevent pathophysiologic effects of intense and prolonged stresses.


Here we report gene expression changes occurring in leukocytes collected from Army Ranger Cadets before and after eight-week Ranger Training. Ranger cadets are exposed to different and extreme physical and psychological stressors of Ranger Training Course, which is designed to emulate extreme battlefield scenarios: sleep deprivation, calorie restriction, strenuous physical activity, and survival emotional stresses—pushing cadets to their physical and psychological limits. The Ranger population provides a rare opportunity to study intense chronic battlefield-like stress, and to contribute to the understanding of intense chronic stress in general. Ranger Training has been shown to impair cognitive function, cause significant declines in 3,5,3′-triiodothyroxine and testosterone, and increase cortisol and cholestero12; 13.


Transcriptomic alterations, in this study, were assayed using cDNA microarrays. Results were corroborated with oligonucleotide, microRNAs, and real-time QPCR arrays, and were confirmed using Quantitative RT-PCR and ELISA. Analyses of functional and regulatory pathways of differentially altered transcripts revealed suppression of immune processes due to battlefield-like stress. Some of stress induced microRNAs, and a number of stress inhibited transcription factors were found to regulate or be modulated by many compromised immune response transcripts. Suppressed immune response genes remained suppressed even after exposure of post-stress leukocytes to mitogenic toxin, SEB. This impaired activation is a clear indicator of anergy, and compromised protective immunity.


Results


Ranger Trainees experience an average daily calorie deficit of 1000-1200 kcal, restricted and random sleep of less than 4 hours per day, strenuous and exhaustive physical toiling and emotional survival stressors. Five of the initial fifteen Trainees enrolled in our study were replaced with five others due to attrition (to maintain 15 study subjects at both time points). All study subjects had complete and differential blood counts performed, and were observed for infections and injuries. By the end of training, Trainees showed significant average weight loss, decreased body mass index and diastolic blood pressure, and significant increase in average body temperature and systolic blood pressure (FIG. 1A); and they showed metabolite patterns typical of severe stress. The vertical lines show the ranges of cell counts. (Normal Ranges are WBC 5-12×103/mm3; NEU 2-8×103/mm3; LYM 1-5×103/mm3; MON 0.1-1×103/mm3; EOS 0.0-0.4×103/mm3; BAS 0.0-0.2×103/mm3.)


Differential and complete blood counts showed small but significant differences between pre- and post-Training cells, yet all were within normal ranges (FIGS. 1B and 1C). To normalize for cell count differences, equal number of pre- and post-Training leukocytes were used for isolation of RNA, and equal amounts of isolated RNAs were used for microarrays, and RT-QPCR assays.


As shown in FIGS. 1B-1C, differential and complete leukocyte counts of soldiers before and after RASP are presented. Differential and complete blood counts for pre- and post[RASP subjects included red blood cells (RBC), white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and baseophils, (BAS). Using comparative t-test, only RBC (P<0.006) and BAS (p<0.02) were significantly changed (reduced) after RASP. The ranges of cell counts including RBC and BAS (shown by the vertical lines) were within normal ranges. Normal ranges are WBC5-12×103 mm−3; NEU 2-8×103 mm−3; LYM 1-5×103 mm−3; MON 0.1-1×103 mm−3; EOS 0.0-0.4×103 mm−3; BAS 0.0-0.2×103 mm−3.


Transcriptome Profiling of Pre- and Post-Training Leucocytes


We used three transcriptome profiling techniques to cross-validate our findings: cDNA and oligonucleotide microarrays, and quantitative real time PCR arrays. Expression profiles were done on total RNAs isolated using two different methods: Trizol (Invitrogen. Inc) and PAXgene, (Qiagen.Inc).


cDNA Microarrays Analyses


To analyze gene expression profiles of leukocytes of Ranger Cadets collected before and after eight-week Training, we used custom cDNA microarrays that contained ˜10 000 well-characterized cDNA probes of 500 to 700 base pairs representing ˜9 000 unique human gene targets. Welch's (unpaired unequal variance) t-test along with false discovery rate (FDR) correction was used on normalized expression data to identify 1 983 transcripts that were significantly changed (q≤0.05), with 1 396 showing ≥1.5 fold change in expression level between pre- and post-Training samples (Table 4). Among 1 396 differentially regulated genes, 288 genes FIG. 2B were significantly changed at q≤0.001, and 87 of these were differentially regulated by >3-fold change. Of these 87 genes, 72 were down-regulated, and 68 of 72 genes have direct role in immune response, including 23 of the 25 most down-regulated genes. These results strongly suggest that Ranger Training stressors suppress the immune response, and this finding was corroborated by functional and pathway enrichments.


Functional enrichments of significantly regulated genes using both hypergeometric test (FDR correction, q≤0.05), and Fishers exact test identified the immune system as the most affected biological process. Apoptosis, stress response, response to wounding, metabolism, hormone receptor signaling (peptide and steroid), cell cycle and unfolded protein response signaling were also significantly associated with altered transcripts. Yet, immune system process was most significantly over-represented (q<1.7E-16), and was associated with 177 differentially regulated genes. Of the 177 genes, 151 were down-regulated, and 26 were up-regulated. Further functional enrichment of the 151 genes indicated that these genes were significantly associated with microbial recognition, inflammation, chemotaxis, antigen presentation, and activation of lymphocytes, mast cells and macrophages (Tables 1). The 26 Up-regulated immune response genes were associated with response to steroid hormone stimulus, regulation of leukocyte activation, complement activation, negative regulation gene expression, and negative regulation of phosphorylation (Table 1).









TABLE 1







Functions significantly associated with differentially regulated immune response


genes that passed Welch's t-test and FDR correction (q < 0.05 and showed >1.3


fold change in post RASP leukocyted compared with pre-RASP leukocytes.









GO-ID
Function
Gene symbol (note these ar symbols and not sequences)










Functions of down-regulated immune response genes









45321
leukocyte activation
MICA, CD8A, CD8B, ELF4, TLR4, ADA, CD74, CD93, CD2, FCER1G,




CD4, SYK, IL4, KLF6, PTPRC, CD3D, IL8, CD3E, RELB, SLAMF7,




CD40, LAT, LCK, CD79A, LCP2


6954
inflammatory response
CXCL1, ITGAL, TNF, TLR2, NFKB1, ITGB2, TLR4, CCL5, CD97,




CCL20, KRT1, IL1B, IL1A, CEBPB, IL8, IL1RN, GRO3, CD40, CCL18,




CD180, C8G, SCYA7, CCL13, CCR7, CYBB, CCR5, CRH, CD14


19882
antigen processing and
HLA-DQB1, MICA, CD8A, HLA-DRB1, RELB, HLA-C, FCGRT, HLA-B,



presentation
HLA-G, CD74, B2M, FCER1G, HLA-DPA1, HLA-DPB1, HLA-DOB, AP3B1,




HLA-DRA


46649
lymphocyte activation
IL4, PTPRC, KLF6, MICA, CD3D, CD8A, ELF4, CD3E, CD8B, RELB,




CD40, SLAMF7, CD74, ADA, LCK, CD2, CD4, CD79A, SYK


30097
hemopoiesis
IL4, PTPRC, KLF6, CD3D, LYN, HCLS1, RELB, IFI16, MYH9, CD164,




CD74, LCK, CD4, SPIB, CD79A, MYST1, SYK, MYST3


52033
pathogen-associated molecular
PF4, CHIT1, TLR2, TLR4, SCYA7, CD14, PF4V1, CLP1, TICAM1,



pattern recognition
FPRL1, FPR1


6935
chemotaxis
IL4, CXCL1, C5AR1, IL8, GRO3, ITGB2, PF4, CCL5, CCL18, SCYB5,




SCYA7, CCL13, CCR7, CCR5, PPBP, CCL20, IL1B, FCER1G, SYK,


42110
T- cell activation
PTPRC, MICA, CD3D, CD8A, CD3E, CD8B, ELF4, RELB, CD74, ADA,




LCK, CD2, CD4, SYK


2274
myeloid leukocyte activation
LAT, IL8, CD93, RELB, FCER1G, TLR4, LCP2


50778
positive regulation of immune
PTPRC, MICA, SLK, FYN, KRT1, TLR2, FCER1G, CD79A, C8G, SYK



response


6959
humoral immune response
PSMB10, CD83, ST6GAL1, TNF, HLXB9, POU2F2, KRT1, AIRE, C8G


1934
positive regulation of
TNF, CCND3, LYN, HCLS1, IL1B, CD4, SYK



phosphorylation


45087
innate immune response
CYBB, IL1R1, SARM1, CLP1, KRT1, TLR2, TLR4, SLAMF7, CD180,




C8G


2252
immune effector process
PTPRC, LAT, MICA, FCN2, KRT1, FCER1G, SLAMF7, CD74, C8G


30593
neutrophil chemotaxis
IL8, FCER1G, IL1B, ITGB2, SYK


7229
integrin- signaling
LAT, ITGAL, ITGAX, ITGB2, MYH9, ITGAM, SYK


45058
T- cell selection
CD3D, CD4, CD74, SYK


1816
cytokine production
IL4, CD4, ISGF3G, CD226, LCP2


6909
phagocytosis
CD93, FCN2, CLP1, FCER1G, CD14


2460
somatic recombination for
IL4, RELB, FCER1G, TLR4, CD74, C8G



adaptive response







Functions associated with up-regulated immune response genes









48545
response to steroid hormones
CEBPA, CAV1, HMGB2, PRKACA, CD24


42326
negative regulation of
CAV1, PRKACA, INHA



phosphorylation


6956
complement activation
C4B, C3, C2


10817
regulation of hormone levels
DHRS2, ACE, FKBP1B


43434
response to peptide hormones
HHEX, PRKDC, PRKACA


2762
negative regulation of myeloid
FSTL3, INHA



leukocyte differentiation


32088
negative regulation of NFkB
POP1, SIVA



activity


51384
response to glucocorticoids
CEBPA, CAV1, PRKACA


16481
negative regulation of
CEBPA, HHEX, CAV1, HMGB2, FST,



transcription
HELLS










Oligonucleotide Microarrays


Gene expression alterations in leukocytes of Rangers before and after Training were also analyzed using PAXgene RNA isolation and oligonucleotide microarrays representing 24 650 human gene probes. This different RNA isolation procedure and microarray assay again showed that the immune system was most significantly affected process. Normalized expression levels were analyzed using Welch's t-test (p<0.05, without multiple correction), and fold change filter (>=1.5 fold). Among 1570 genes (that passed these filters), 104 genes were associated with the immune response processes including microbial recognition, chemotaxis, inflammation, antigen presentation, and T-cell, B-cell and NK-cell activations (FIGS. 3A-E & Table 5).


Real Time Quantitative PCR Array


We used real time quantitative PCR (QPCR) arrays to confirm differential expression of genes identified by cDNA and oligonucleotide microarrays, and to survey additional immune related genes. Assay results of PCR arrays that contained more than 160 genes in antigen presentation and NFkB signaling pathways (RT2 Profiler™ PCR Arrays, SABioscience, MD) verified down-regulation of 116 immune response genes, consistent with microarray data (Tables 3A, 3B and 4). The vast majority of the genes important for microbial pattern recognition, inflammation, antigen presentation, T-cell activation and transcription factors related to immune response were suppressed across cDNA, oligonucleotide and PCR arrays (FIGS. 3A and 3B)


Referring to FIGS. 3A-E, genes are shown that are associated with pattern recognition receptors (FIG. 3A); inflammatory response (to scale the graph, fold changes of −15.2 and −23.8, labeled * and **, respectively, were assigned a values of ˜5 and 6, respectively (FIG. 3B); antigen preparation and presentation (*fold change: −12.3; assigned value ˜−5 for scaling the graph) (Fig. C); transcription factors (*fold change: −12.6; **fold change: −12.3; ***fold change: −14; these were adjusted to around −5 for scaling the graph) (FIG. 3D); T-cell activation, differentiation and proliferations. Expression profiles of genes shown in pannels A-E were assayed using SABiosciences RT2Profiler™ (PAHS 406 and PHAS 25) PCR Arrays, cDNA microarrays, and oligonucleotide microarrays (FIG. 3E). Total RNA samples were isolated using Trizol reagents for cDNA microarray analysis, and total RNA samples used for PCR and oligonucleotide arrays were isolated from blood samples collected in PAXgene tubes. (Note: PCR arrays were carried out on subjects participated throughout our study, and fold changes for these figures were calculated on data from both round subjects).


Real Time Quantitative PCR


Additional quantitative real-time PCR assays were carried out using specific primer pairs to confirm 10 representative genes among 1396 significantly altered genes shows number of genes that passed Welch's t-test at different q-values (FDR corrected p-values) and Fold Change cut-offs) (FIG. 2A)(Table 2). Real-time QPCR Assayed and confirmed genes included IL1B, IL2RB, CD 14, HLA-G, RAP1A, AQP9, ALB, CSPG4, CDC2, A2M, and GAGE2. Individual real-time QPCR results confirmed and validated these differentially expressed genes identified by cDNA arrays (FIG. 4A).



FIG. 4A shows Real time PCR reactions for each gene were carried out with three or more replicates. The microarray data were from Trizol RNA isolation and cDNA microarrays (*p-values<10−5, **p-values<0.0002, ***p-value<0.02). The p-values given here were taken from the microarray analyses obtained after FDR correction.


Genes Associated with Microbial Recognition


Genes associated with microbial pattern recognition were significantly suppressed in post-Training leukocytes (Table 5, & Tables 1 & FIG. 5D). These genes include Toll-like receptors (TLR 2, 3, and 4), CD14, CD93, chitinase 1 (CHIT1), formyl peptide receptor 1 (FPR1), formyl peptide receptor like 1 (FPRL1), dicer1 (DICER1), cleavage and polyadenylation factor I subunit (CLP1), platelet factor 4 (PF4), platelet factor 4 variant 1 (PF4V1), toll-like receptor adaptor molecule 1 (TICAM1), and myeloid differentiation primary response gene 88 (MYD88). TLR6 was down-regulated but it did not pass the FDR correction filter.


CD 14, along with TLR4/TLR4 and TLR2/TLR6, recognize lipopolysaccharides and peptideoglycans, respectively. TLR3, CLP1 and DICER1 bind to double stranded viral RNAs. TLR9 and CD93 recognize unmethylated CpG dinucleotides of bacterial DNA, and patterns of apoptotic cells, respectively. FPR1 and FPRL1 bind bacterial N-terminal formyl-methionine peptides. CHIT1 recognizes fungal and pathogens with chitin patterns. PF4 and PF4V1 recognize patterns of plasmodium and tumor cells. TICAM1 and MYD88 are important cytosolic adaptor molecules of microbial pattern recognitions. Transcripts of these genes were down-regulated suggesting a compromised innate immune response with regard to microbial recognition.


Genes Associated with Chemotaxis and Inflammation


Stress suppressed transcripts associated with chemotaxis and inflammation included interleukins (IL 1A, IL1B, IL4, IL8), interleukin receptors (IL1R1, IL1RN, IL2RB, IL10RA), chemokine (C-X-C motif) ligands (CXCL 1), chemokine (C-C motif) ligands (CCL13, CCL18, CCL20), tumor necrosis factor alpha (TNFα), TNF receptor super-family members 1B, 10B and 10C (TNFRSF1B, TNFRSF10B and TNFRSF10C), TNF superfamily members 3, 8, (LTB, TNFSF8), complement component 8 gamma (C8G), cytochrome b-245 beta (CYBB), CD97 and interferon gamma receptor (IFNGR2) (Tables 1 & 5).


Genes Associated with Activation of Myeloid Leukocytes


Tables 1 & 5 show suppressed transcripts associated with activation of mast cells and macrophages. These included toll-like receptors (TLR4), TNF, LAT, lymphocyte cytosolic protein 2 (LCP2), SYK, CD93, and IL4 RELB. Suppressed genes associated with inflammatory responses (ILL CD14, INFGR1) were also significantly associated with activation of myeloid cells. Differentiations of myeloid leukocytes were significantly associated with interferon gamma inducible proteins 16 and 30 (IFI16), myosin heavy chain 9 (MYH9), IL4, Spi-B transcription factor (SPIB), NFkB3, MYST histone acetyltransferases (MYST1 and 3), TNF, PF4, hematopoitic cell-specific lyn substrate 1 (HCLS1), V-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN) and V-maf (musculoaponeurotic fibrosarcoma) oncogene homolog b (MAFB). Down-regulation of hemopoietic transcription factors (MAFB and HCLS1) and CSF1R may indicate less viability of myeloid cells to expand or to replenish. Suppression of mRNAs of these genes suggests poor activation, differentiation and proliferation of myeloid leukocytes in response to infection, and hence poor innate and adaptive immune responses.


Genes Associated with Antigen Presentation


Genes associated with antigen preparation encompass MHC classes (I & II), CD1s, B-cell co-receptors and integrins (Tables 1 and 5). Transcripts of MHC class I (HLA-B, HLA-C, HLA-G, beta-2-microglobulin (B2M)), MHC class II (HLA-DRB1, HLA-DRA, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, CD74, HLA-DOB), B-cell co-receptors (CD79A, CD79B), Ig heavy constant gamma 1 (IGHG1), Ig heavy constant alpha 1 (IGHA1), MHC class I polypeptide related sequence A (MICA), adaptor-related protein complex 3 beta1 (AP3B1), intercellular adhesion molecules 1, 2 and 3 (ICAM1, ICAM2, ICAM3) were down-regulated implying poor antigen preparation and presentation, and hence impaired adaptive immune response.


Genes Associated with Activation of Lymphocytes


Suppressed transcripts associated with T-cell activation, differentiation and proliferation included TCR co-receptors (CD4, CD8α, CD8β, CD3ϵ, CD3δ, CD247), linker for activation of T cells (LAT), TCR signaling molecules [protein kinase c theta (PRKCQ), protein tyrosine phosphatase receptor type C (PTPRC), C-SRC tyrosine kinase (CSK), spleen tyrosine kinase (SYK) lymphocyte specific protein tyrosine kinase (LCK)], integrins CD2, CD44, integrin alpha L, M and X (ITGAL, ITGAM, ITGAX), and cyclin D3 (CCND3) (Tables 1 & 5).


Interleukin 4, SYK, PRKCD, CD40, PTPRC, cyclin-dependent kinase inhibitor 1A (CDKN1A), Kruppel-like factor 6 (KLF6), SLAM family member 7 (SLAMF7), and killer cell Ig-like receptor three domains long cytoplasmic tail1 (KIR3DL1) were significantly associated with activation, differentiation and proliferation of B-cells, and NK-cells (Tables 1 & 5).


Transcription Factors Associated with Immune Responses


Transcription factors that are important regulators of immune response genes were down-regulated. Suppressed factors included nuclear factor kappa B family (NFkB1, NFkB2, RELA, RELB), interferon regulatory factors 1, 5, 7, 8 (IRF1, IRF5, IRF7 and IRF8), signal transducer and activator of transcription (STAT2, STAT6), and SP transcription factors (SP1, SP140) (Tables 1 & 5). In addition, transcription factors GA binding protein alpha (GABPA), POU class 2 homeobox 2 (POU2F2), p53 (TP53), p53 binding protein 1 (TP53BP1), early growth response 2 (EGR2), splicing factor 1 (SF1), and hypoxia inducible factor 3 and alpha subunit (HIF3A) were down-regulated. Up-regulated transcription factors included hepatocyte nuclear factor 4 alpha (HNF4A) hepatic leukemia factor (HLF), sterol regulatory element binding transcription factor 2 (SREBF2) transcription factor AP-2 alpha (TFAP2A), transcription factor 7-like 2 (TCF7L2) and NF-kappa-B inhibitor-like 2 (NFKBIL2) (Tables 1 & 5).


ELISA Assays of Plasma Proteins


Plasma concentrations of insulin-like growth hormones 1 and 2 (IGF1 and IGF2), prolactin (PRL), tumor necrosis factor alpha (TNF), and enzymatic-activity of superoxide dismutase 1 (SOD 1) were determined by ELISA to examine gene expression alterations at the protein level. Relative quantities of proteins, and levels of transcripts profiled by cDNA and oligonucleotide microarrays were compared (FIG. 4B). Reduced IGF1 has been shown to be a biomarker of negative energy balance under conditions of multiple Ranger Training stressors12, and IGF1 transcript in leukocytes and protein in plasma are reduced after Training. Plasma concentration of PRL was up-regulated while transcriptome profiling showed down-regulation by microarray analyses, suggesting differential regulation of prolactin at transcription and translation levels.



FIG. 4B shows plasma concentrations of prolactin (PRL), insulin-like growth factors I and II, tumor necrosis factor alpha (TNF α) and enzymatic activity of superoxide dismutase 1 (SOD 1) were assayed using nine biological replicates and three experimental replicate samples corresponding to each biological replicate for each of these proteins. The IGF-I depletion is consistent with other studies that measured its plasma concentration on similar subjects13 (*p-values<0.003, **p-values<0.04, ***p-value <0.0002).


Response of Leukocytes to Ex Vivo Treatment of Staphylococcal Enterotoxin B



Staphylococcus enterotoxin B (SEB) is a superantigen, and a potent T cell activator known to induce proinflammatory cytokine release in vitro14. Leukocytes of Ranger Trainees collected before and after Training were challenged ex vivo with SEB and immune response transcripts were analysed. In pre-Training leukocytes, SEB toxin induced majority of immune response genes (FIG. 5A). However, in post-Training leukocytes, stressed suppressed immune response genes showed no sign of re-activation even after ex vivo exposure to SEB (FIG. 5A). Rather SEB seemed to further suppress expression of many of these transcripts. Impaired response of post-Training leukocytes to SEB is consistent with suppression of immune response pathways and networks revealed by transcriptome analyses.


In FIG. 5A, expression of immune response genes in leukocytes exposed ex vivo to SEB is shown. Leukocytes isolated from whole blood were treated with SEB (˜106 cells ml−1 in RPMI 1640 and 10% human AB serum at a final concentration of 100 ng ml−1 SEB). Total RNA was isolated using Trizol and expression levels were profiled using cDNA microarrays. Shown here are the 151 RASP-suppressed immune response genes that passed Welch's test and FDR correction (q<0.05). (a) Lanes left to right: pre-RASP samples not exposed to SEB (control), pre-RASP samples exposed to SEB, post-RASP samples not treated with SEB, post-RASP samples exposed to SEB. For comparative visualization purpose, expression values of the other groups were transformed against the Pre-RASP control samples (black lane). Heat map of the same data without transformation is given in the supplement. (b) Expression values in SEB exposed leukocytes (in both the pre- and post-RASP conditions) were compared with the corresponding SEB untreated groups (pre-RASP control and post-RASP stressed groups). (c) Heat map of 151 immune response genes in SEB treated groups (in both pre- and post-RASP leukocytes) clustered after subtraction of the corresponding baseline responses (cluster after subtraction of their expressions in the corresponding untreated groups shown in lane (b). Lane c clearly shows pour response of post-RASP leukocytes towards SEB exposure compared with pre-RASP leukocytes.


MicroRNA Arrays


Differentially regulated microRNAs (miRs) in pre- and post-Training samples were assayed using Agilent's human microRNA chip containing ˜15 000 probes representing 961 unique miRs. Comparison of 535 miRs (that passed normalization and flag filters) using Welch's t-test at p<0.1 with a 1.3 fold change cutoff gave 57 miRs (FIG. 5C). MicroRNA target scan was used to identify high-prediction and experimentally proven targets of these differentially regulated miRs. Among up-regulated miRs, hsa-miR-155 (p<0.08) and hsa-let-7f (p<0.1), were shown to target many suppressed transcripts, including transcription regulators of genes important for dendritic cell maturation and glucocorticoid receptor signaling. Expression of miR-155 was suppressed in pre-Training samples exposed to SEB, but it was induced in post-Training samples treated with SEB (FIG. 6). Other stress-induced miRs were predicted to have regulatory connection with stress-affected inflammatory cytokines, antigen-presenting molecules, and transcription regulators of genes involved in immune response (FIG. 5D). Stress-suppressed miRs—miR-662, miR-647, miR-876-5P, miR-631, miR-1296, miR-615-3P, and miR-605—have a number of regulation targets among stress-regulated genes involved in NFkB activation pathways (FIG. 5E). In FIG. 5E enriched pathways: IL-7 and IL-8 signalings, and NFkB activation pathways are shown. No targets were identified for two highly suppressed miRs, miR-1910 and 1909*.



FIG. 6 shows predicted targets of miR-155 and hsa-let 7f families. In FIG. 6, expression levels of hsa-miR-155 and hsa-let-7f in pre-RASP (control), post-RASP (stressed) and pre-RASP exposed to SEB, and post-RASP exposed to SEB groups. Sequences of mature miR-155 and let-7f are also shown.


See also FIG. 5B for predicted and experimentally observed targets of RASP-regulated micro RNAs. 57 microRNAs passed Welch's T-test (P<0.1) and 1.3 fold change. Most (46 of 57) miRs were downregulated, and 11 miRs were upregulated in post-RASP leukocytes.


Expression Data Based Prediction of Transcription Factors and Target Genes


Computational & data analyses tools, and databases (see Materials and Methods) were used for empirical and predictive association of transcription factors (TFs) and their regulatory targets among stress-altered genes. Activated or inhibited TFs, common regulatory sites of target genes, and prediction z-scores of identified TFs were computed based on 1369 differentially regulated genes obtained from cDNA array data (Table 2). TFs at the top of stress-inhibited list (IRF7, RELA, NFkB1, RELB, CREB1, IRF1, HMGB1 & CIITA) and their differentially expressed targets (Table 2) were found to be involved in inflammation, priming of adaptive immune response, and glucocorticoid receptor signaling (FIG. 7A and FIG. 7B). FIG. 7B shows transcription factors targeting RT-PCR assayed and differentially regulated genes. Both MYC and NR3C1 were predicted to be activated (according to prediction z-score value, which were >2.5). The top function associated with these targets were apoptosis of leukocytes, hematopoisis, proliferation of blood cells, immune response; and top pathways are given in the table immediately below in Table A:









TABLE A







Network showing MYC and NR3C1 targets among immune response genes












Symbol
EntrezID
FC
Family
Drugs
Entrez Gene Name















ACTB
60
−1.73
other

actin, beta


AKT1
207
−3.13
kinase
enzastaurin
v-akt murine thymoma viral







oncogene homolog 1


CASP1
834
−1.58
peptidase

caspase 1, apoptosis-related cysteine







peptidase


CD44
960
−2.33
other

CD44 molecule (Indian blood group)


CDKN1A
1026
−2.92
kinase

cyclin-dependent kinase inhibitor 1A







(p21, Cip1)


HLA-A
3105
−2.63
other

major histocompatibility complex,







class I, A


ICAM1
3383
−2.09
transmembrane

intercellular adhesion molecule 1





receptor


IL8
3576
−1.53
cytokine

interleukin 8


ITGAM
3684
−2.02
other

integrin, alpha M (complement







component 3 receptor 3 subunit)


ITGB2
3689
−1.29
other

integrin, beta 2 (complement







component 3 receptor 3 and 4 subunit)


MYC
4609

transcription

v-myc myelocytomatosis viral





regulator

oncogene homolog (avian)


NFKB1
4790
−1.56
transcription

nuclear factor of kappa light





regulator

polypeptide gene enhancer in B-cells 1


NFKB2
4791
−1.44
transcription

nuclear factor of kappa light





regulator

polypeptide gene enhancer in B-cells 2







(p49/p100)


NR3C1
2908

ligand-dependent
rimexolone,
nuclear receptor subfamily 3, group





nuclear receptor

C, member 1 (glucocorticoid







receptor)


RELA
5970
−1.72
transcription
NF-kappaB
v-rel reticuloendotheliosis viral





regulator
decoy
oncogene homolog A (avian)


TLR2
7097
−3.14
transmembrane

toll-like receptor 2





receptor


TNF
7124
−3.74
cytokine
adalimumab
tumor necrosis factor


TNFAIP3
7128
−3.74
enzyme

tumor necrosis factor, alpha-induced







protein 3


TNFRSF10B
8795
−1.71
transmembrane
tigatuzumab
tumor necrosis factor receptor





receptor

superfamily, member 10b









Regulatory sites for a number of transcription factors including SP1, CREB1, ATF6, cEBP, and binding sites for the defense critical—NFkB transcription factors complex, and stress response sites (STRE) were among common regulatory motifs identified for some of stress-suppressed genes, STRE site being predicted to be regulated by MAZ and MZF1. Stress activated factors included GFI1, MYC, FOXM1, GLI2, MAX and HNF1A (Table 2), and these factors induced genes important for hormone biosynthesis and suppressed immune related genes.



FIG. 7A shows transcription factors predicted to be inhibited by battlefield stressors and their targets among stress modulated genes. Shown here are transcription factors predicted to be inhibited by battlefield stessors (Table 2) and their targets among 288 stress-affected transcripts (filtered using Welch's t-test and FDR, q<0.001, and >1.5 fold change). Enriched function and pathways of these transcripts include activation and proliferation of leukocytes, maturation of dendritic cells (DCs), communication between innate and adaptive immunity, glucocorticoid receptor signaling and antigen presentation pathway.









TABLE 2







Predicted transcription factors and targets identified among 1396 genes that


passed Welch's t-test, FDR correction (q ≤ 0.05) and 1.5 fold change cutoff.











z-
p-



TF
score
value
target molecules in dataset










activated transcription factors and targets










GFI1
3.1
4.1E−04
CASP1, CDKN1A, CEBPA, GUSB, ICAM1, IL1A, IL1B, IL8, IRF1, MMP7, NFKB1,





NFKB2, RELA, RELB, TRAF3


MYC
3
1.6E−17
ACAT1, ACTB, ACTN1, AFP, AHCY, ALB, BCAT1, BCL6, BIN1, BIRC2, BIRC5,





CAPN2, CASP1, CASP10, CAV1, CCND1, CCND3, CD44, CD48, CDC20, CDH2, CDK1,





CDK11A/CDK11B, CDKN1A, CEBPA, COL14A1, COL1A1, CSPG4, CYFIP2, DDX11/





DDX12, DDX3X, DDX5, DUSP6, EDN1, EGR2, EIF2S2, F2, F3, FBN1


FOXM1
2.8
4.8E−05
BIRC5, CCND1, CDC20, CDK1, CDKN1A, CENPA, CENPF, FOXM1, KDR, KIF20A,





MMP2, PLK4, TGFBR2


GLI2
2.7
3.2E−02
CCL5, CCND1, CDK1, CDKN1A, IL1B, ITGB1, KRT1, KRT17, PTCH1, SFRP1


MAX
2.4
1.4E−03
BCL6, CDKN1A, EDN1, FTH1, ID1, KLF6, LAMP2, MTHFD1, PDGFRB, SERINC3,





TSC2, UBE2C


HNF1A
2.1
3.6E−02
ABCC2, AFP, AKR1C4, ALB, ANPEP, APOB, AQP9, BCL6, C2, CCND1, DPP4, DUSP6,





FAM107B, FBXO8, FGA, FGB, G0S2, GNB2L1, HNF4A, IGFBP1, KIF20A, KIR3DL1,





LCAT, MTHFD1, NAPA, PDK1, PFKP, PIH1D1, PRLR, PZP, SERPINA7, SLC26A1,





SLCO1A2, SSTR4, TRA@, UQCRC2, UROD







inhibited transcription factors and targets










CEBPB
−2.2
1.3E−11
ACTG2, ALB, C3, CCL5, CCND1, CD14, CDKN1A, CEBPA, CEBPB, COL1A1, CP,





CSF1R, CTSC, CXCL5, CYP19A1, DDX5, DEGS1, FTL, HLA-C, HP, HSPD1, ICAM1,





ID1, IGFBP1, IL1B, IL1RN, IL8, INMT, IRF9, LAMC1, LCP2, LYN, MGP, MIA,





PCTP, PDGFRA, PEA15, PLAUR, PPARD, PRKCD, PR


JUNB
−2.3
2.8E−03
ACLY, CAV1, CCND1, CD68, CDC20, COL1A1, CYP19A1, FTH1, MMP2, MVD, NCF2,





PTBP2, RELB, SCD


CIITA
−2.4
1.4E−07
B2M, CCND1, CD74, COL1A1, HLA-B, HLA-DOB, HLA-DPA1, HLA-DQA1, HLA-DQB1,





HLA-DRA, HLA-DRB1


POU2AF1
−2.6
3.4E−03
BCL6, CCND3, CD79A, CD79B, IGHA1, IGHG1, LCK, TRAF3


STAT1
−2.8
8.2E−12
A2M, B2M, BIRC5, BTG1, C3, CASP1, CASP2, CASP4, CCL5, CCND1, CCND3,





CCR7, CD14, CDKN1A, DPP4, FCER1G, GATA3, GBP1, GZMB, HLADRB1, ICAM1,





IFIT3, IL1B, IL8, IRF1, IR5, IRF7, IRF9, LY96, NFE2, PDGFRB, PF4, PRL, PSMB10,





PTGS2, SMAD7, SOCS3, STAT2, TLR4, TN


FOXO3
−2.8
1.8E−04
BIRC5, CCND1, CDKN1A, CTGF, CYR61, FOXM1, FOXO1, GPX1, IER3, IGFBP1,





IL8, NAMPT, NOS3, SATB1, SOD2, TNFRSF1B, TXNIP, UBC, UBE2C


SPI1
−2.9
1.5E−10
ACTB, CCR7, CD14, CD68, CD79A, CD79B, CEBPA, CSF1R, CYBB, DUSP6, FCER1G,





FLI1, FTH1, GNB2L1, GPX1, IGL@, IL1B, IL1RN, IRF9, ITGA5, ITGAM, ITGB2,





MCL1, MMP2, NCF2, P2RY1, PIK3CG, PTGS2, PTPRC, RELA, TK1, TLR2, TLR4


IFI16
−3
1.8E−04
CCL5, CCND1, CDKN1A, EDN1, GPX1, ICAM1, IFI16, IL1B, IL1RN, IL2RB, IL8,





RPA3, STAT2


HMGB1
−3.1
1.6E−06
CD83, CDKN1A, CXCL5, HLADRB1, ICAM1, IL1A, IL1B, IL8, MIA, PTGS2, RELB,





SIRT1, TLR2, TLR4


IRF1
−3.2
1.0E−06
B2M, CASP1, CASP2, CCL5, CCND1, CDKN1A, CYBB, EIF4A3, HLA-G, IFIT3,





IL1B, IL8, IRF1, IRF5, IRF7, IRF9, LTB, NFE2, PF4, PSMB10, PTGS2, SOCS7,





STAT2, TRIM22


CREB1
−3.4
1.5E−08
ARPC3, ATP6V0B, BTG2, CCND1, CD3D, CD4, CD68, CD79A, CDH2, CEBPB, CYP19A1,





CYP51A1, CYR61, DIO2, EDN1, EGR2, FN1, FOSB, GALNT1, HERPUD1, HLA-





DRA, HLA-G, HMGCS1, HSPA4, IL1B, INHA, IRF7, MCL1, PDE3B, PDGFRA, PER1,





PRL, PTGS2, SCD, SLC16A1, SLC2A4, SOD2, TF, TFAP2A, UPP1


NFKB1
−3.4
1.9E−08
A2M, ADORA1, AKR1B1, B2M, BTG2, CCL5, CCND1, CDKN1A, COL2A1, CYBB, FANCD2,





GATA3, GNB2L1, ICAM1, IER3, IFNGR2, IGHG1, IL1B, IL1RN, IL8, IRF1, LTB, MICA,





NFKB1, NFKB2, PLK3, POU2F2, PRKACA, PTGS2, RELA, RELB, SOD2, TK1, TLR2,





TNFAIP3


RELA
−3.7
3.1E−17
A2M, ABCG2, ACTA2, AFP, B2M, BIRC2, BTG2, CAV1, CCL5, CCND1, CCR7, CD44,





CDKN1A, COL2A1, CXCL1, CYBB, CYP19A1, DIO2, EDN1, EWSR1, F3, GDF15, HLA-B,





ICAM1, IER2, IER3, IFNGR2, IGHG1, IL1A, IL1B, IL1RN, IL8, INPP5D, IRF1, IRF7, L


IRF7
−3.9
3.0E−03
CASP4, CCL5, GBP1, IFI16, IFIT3, IRF1, IRF9, ISG20, ITGAM, MCL1, NAMPT, PSMB10,





STAT2, TLR4, TMPO, TRIM21, TRIM22





Abbreviation: TF, transcription factor/regulator.


Regulation z-score; P-value overlap.






SUMMARY

Most immune response genes were down-regulated in post-Training leukocytes compared to pre-Training leukocytes. Functional enrichment of these down-regulated genes revealed their involvement in microbial pattern recognition, cytokine production and reception, chemotaxis, intercellular adhesion, immunological synapse formation, regulation of immune response, and activation and proliferation of immune cells (FIG. 8).



FIG. 8 demonstrates a functional network of differentially expressed genes connected by their sub-functions in the immune system. The network shows enriched functions of genes involved in immune responses: activation of immune cells, differentiation, proliferation, antigen presentation, and infection directed migrations. Genes involved in all these functions were down regulated by the Ranger Training stressors. Each node represents a category of gene ontology of the pathways of the immune system. Node sizes are proportional to the number of genes belong to each category according to gene ontology, and intensity of node indicate significance of hypergeometric test after Bonferroni correction (q≤0.05). The pattern circles show more significant the enrichment than the solid white circles.


Our data suggest that stress induced suppression of microbial patterns of innate immunity (FIG. 9A) may impair infection-directed maturation, activation, inflammatory response, motility, and proliferation of myeloid cells (FIGS. 9B & 9C) These impaired innate cells may also fail in priming the adaptive arm of immune response (FIG. 10A).


In FIG. 9A, shows altered immune response genes involved in pattern recognition, viral, antibacterial effector (humoral) responses.


In FIG. 9B, roles of stress down regulated genes in the cellular pathways of immune response are shown. Flat-ended arrows represent suppression of the corresponding pathway (biological process). Microbial recognition receptors, inflammatory cytokines (IL1, IL1R, TNFα, CD40), chemotaxis (IL8, IL8R, RANTES, CCR5, CCR7), lymphocyte recruitment (IL4, IL 12), and production of effector molecules (INFγ, IL2, IL2RB) were down regulated after Ranger Training


In FIG. 9C, actions of secreted cytokines on other leukocytes are shown. Impaired activity of suppressed IL-1 other myeloid cells to secret antimicrobial effector molecules; depleted concentration gradient of IL-8 providing curtailed guidance to neutrophils and NK cells to sites of infection, and suppressed IL-8 and RANTES unable to recruit and induce maturation of dendritic cells (for antigen presentation); suppressed transcripts important for T-cell polarization (cellular or humoral) may mean deprivation of the host under stress from having protective immunity.



FIGS. 10A and 10B show stress-suppressed genes involved in antigen presentation and synapse formation. FIG. 10A shows antigen presentation pathways: This KEEG pathway taken via IPA was colored for the 288 stress-regulated genes that passed Welch's t-test, FDR correction (q≤0.001) and changed by ≥1.5 fold (between pre- and post-Training groups).



FIG. 10B shows expression of genes important for immunological synapse formation; suppression of transcripts important in antigen preparation, presentation, chemotaxis, intercellular binding, antigen reception, and downstream signaling (the gene labeled solid nodes) may have impaired formation of productive immunological synapse, and hence the poor response of post-Training leukocytes to SEB challenge although SEB toxin is presented without undergoing intracellular preparation, antigen presenting molecules of the synapse were suppressed.


Adaptive cells' antigen receptors, co-receptors, signal transducers, intercellular adhesion molecules, and chemokine receptors were highly suppressed (FIG. 10B). It is less likely that these stress-debilitated lymphocytes can be activated, proliferated, differentiated, and clonally expanded to amount defense response against infections as confirmed by impaired response of post-Training leukocytes to SEB exposure.


Discussion


Suppression of transcripts of critical immune response pathways, and regulatory networks are consistent with impaired innate and adaptive immune responses, including cellular and humoral immunity, as a result of battlefield-like stress.


Down-regulation of transcripts involved in Toll-like receptor, and chemokine and chemokine receptor signaling pathways indicate suppressed inflammatory response, impaired maturation of antigen presenting cells (APCs), impaired affinity maturation of integrins, and impaired migration, extravasation & homing of APCs and T-cells to nearby draining lymph nodes or infection sites.


Antigen preparation and presentation was the most suppressed pathway among immune response processes (FIG. 11). FIG. 11 shows canonical pathways significantly associated with stress-regulated genes that passed Welch's t-test and FDR correction (p<=0.001) and 1.5 fold change. Numbers on the right side indicate total # of genes in the pathway. Suppression of antigen presentation, T-cell receptor and integrin pathways indicate lack of productive immunological synapse formation (poor MHC-restricted antigen recognition and T-cell activation), leading to impaired adaptive and effector immune responses. Particularly, suppression of transcripts involved in cytoskeleton-dependent processes (chemokine guided migration, integrin-mediated adhesion, immunological-synapse formation, cellular polarization, and actin-microtubule aided receptor sequestration and signaling) curtails the dynamic cellular framework of T-cell activations (FIG. 10).


Unlike reports of differential regulations of Th1 and Th2 type responses observed in college students on the day of a stressful examination15, and in caregivers of chronically sick relatives16, our data suggest that battlefield-like stressors impair not only Th1 but also Th2 type responses as shown by suppressed transcripts of TLR2 and 4, and the cytokines IL4, IL4R and IL10RA in post-Training leukocytes. Suppression of inflammatory molecules (e.g., IL1A & 1B, and IL1R1, TNF members and TNF receptors, and NFkB class of factors), and Th2 classes of cytokines show features of battlefield-like stress that are distinct from acute and psychological stresses.


Previously miR-155 is reported to be proinflammatory. MiR-155 (−/−) mice are highly resistant to experimental autoimmune encephalomyelitis17, and show suppressed antigen-specific helper cell, and markedly reduced articular inflammation18. Here, miR-155 transcripts were elevated in post-Training leukocytes (with or without SEB exposure), but its expression was suppressed by SEB in pre-training leukocytes (FIG. 6).


It seems that miR-155 is anti-inflammatory in humans exposed to stress and SEB toxin. Regulatory connection of miR-155 to many of stress-suppressed inflammatory cytokines may indicate its involvement in regulation of these cytokines, and glucocorticoid receptor elements, and modulate maturation of antigen presenting cells under battlefield-like stress.


Poor response of post-Training leukocytes to SEB ex vivo challenge is consistent with suppressed expression of MHCs, T-cell receptors, co-receptors and integrins which are important for activations of APCs and T-cells. Overall, our results clearly demonstrated that battlefield-like stressors suppress a broad spectrum of immune system process. This suppression of broad categories of immune response pathways may explain why chronically stressed individuals show poor vaccine responses and susceptibility to infections.



FIGS. 12-15 were generated from nearest shrunken centroid prediction. The Nearest Shrunken Centroid (NSC) classifier (predictor) is a robust21-22 way of identifying genes specific to a certain agent in the presence of other infections or conditions23. NSC was used successfully to identify cancer biomarkers24-25 and other disease sub-typing26-27.



FIG. 12 is a graphical representation of Nearest shrunken centroid (NSC) ranked genes when stressed and control groups compared. The length of the horizontal bars indicate the absolute value of the score (the bigger the absolute value of the score the longer the horizontal bar, and the direction indicate the gene expression direction (left oriented bar indicate down-regulated and right oriented bar up-regulated genes). Here only two groups are compared and the opposite orientations of the horizontal bars indicate that these genes discriminate between the two compared groups.



FIGS. 13A and 13B are graphical representations of NSC algorithm identified genes which can discriminate stress and other conditions (dengue virus exposure, Yersinia pestis or plague infection and SEB toxin exposure; and also unexposed control group). The direction and length of the horizontal bars is given in FIG. 12. As shown in FIGS. 13 A&B there are 69 genes including 10 specific to the other pathogens that are shown by the corresponding horizontal bars.



FIG. 14 shows misclassification error versus threshold (cut-off) values, each line representing each condition. Here the stress (black line) has the lowest misclassification error beyond the threshold value of around 2.6. That means, genes ranked from one to about 260 can discriminate stress from other conditions (shown here). But in our case we took the top ranked genes (even though many more can also be potential stress biomarkers).



FIG. 15 is a graph showing that identified genes were cross-validated to ascertain that they were not included by mere chance. The more open circles (under stress) being separated from other shapes indicate that these genes discriminate stressed individuals from other patients (samples collected from patients exposed to other pathogens or control group). Though there is shown in FIG. 15 only 114 samples, the total number of samples used for prediction were 141.


Conclusion


Suppressed expression of genes critical to innate, humoral and cellular immunity is an indicator of compromised protective immunity as confirmed by impaired response of post-Training leukocytes to SEB challenge. Numbers and ratios of different subpopulations of leukocytes being within normal ranges, our observation (of anergic leukocytes of severely stressed individuals) draws some caution on current diagnostic practice of counting immune cells to ascertain integrity of the immune system, and its ability of protection against infection.


On the basis of suppressed inflammatory molecules and pathways, we hypothesized that exposure to battlefield-like and similar stresses may make exposed individuals less susceptible to autoimmune diseases, and sepsis; yet they may easily succumb to toxin or infection since their protective immunity already depleted.


Characterization of molecular signatures of stress pathologies can potentially reveal biomarkers and new pharmacologic targets for improving adaptation to stress and preventing stress-induced pathogenesis. Results such as ours together with proteomic analyses may yield novel preventative, prognostic and therapeutic opportunities to intervene the negative consequences of stress on heath.


Materials and Methods


Blood Sample Collection


Whole blood (from each subject) was drawn in Leucopack tubes (BRT Laboratories Inc., Baltimore, Md.) before and after the eight-week Training, and immediately spun at 200×g for 10 minutes. The concentrated leukocyte layer (buffy coats) was collected and treated with TRIzol™ reagent (Invitrogen, Carlsbad, Calif.) for RNA isolation and then stored at −80° C. Differential and complete blood counts (CBC) were obtained immediately after blood collection using a hemocytometer, and subsequently using an ABX PENTRA C+ 60 flow cytometer (Horiba ABX, Irvine, Calif.). Blood samples were also collected in PAXgene™ Blood RNA Tubes (VWR Scientific, Buffalo Grove, Ill.) for direct RNA isolation.


RNA Isolation


For cDNA microarray analysis, total RNA was isolated using the TRIzol™ reagent according to the manufacturer's instructions. The RNA samples were treated with DNase-1 (Invitrogen, Carlsbad, Calif.) to remove genomic DNA and were re-precipitated by isopropanol. The TRIzol™ isolated RNA was used in cDNA microarrays analysis19. For oligonucleotide microarrays, total RNA was isolated using PAXgene tubes following the manufacturer's protocol. The PAXgene tube contains a proprietary reagent that immediately stabilizes RNA at room temperature (18-25° C.) without freezing. Isolated RNA samples were stored at −80° C. until they were used for microarray and real time PCR analyses. The concentration and integrity of RNA were determined using an Agilent 2000 BioAnalyzer (Palo Alto, Calif.) according to manufacturer's instructions. The ArrayControl RNA Spikes from Ambion (Austin, Tex.) were used to monitor RNA integrity in hybridization, reverse transcription and RNA labeling.


cDNA Synthesis, Labeling, Hybridization and Image Processing


RNA was reverse transcribed and labeled using Micromax Tyramide Signal Amplification (TSA) Labeling and Detection Kit (Perkin Elmer, Inc., Waltham, Mass.) following the manufacturer's protocol. The slides were hybridized at 60° C. for 16 h (for cDNA microarrays and Trizol isolated RNA) and at 55° C. for 16 h (for oligonucleotide microarrays and PAXgen isolated RNA). Hybridized slides were scanned and recorded using a GenePix Pro 4000B (Axon Instruments Inc., Union City, Calif.) optical scanner, and the data were documented using Gene Pix 6.0 (Axon Instruments Inc, Union City, Calif.).


Preparation of cDNA Microarrays


Human cDNA microarrays were prepared using sequence-verified PCR elements produced from ˜10,000 well-characterized human genes of The Easy to Spot Human UniGEM V2.0 cDNA Library (Incyte Genomics Inc., Wilmington, Del.). The PCR products, ranging from 500 to 700 base pairs, were deposited in 3× saline sodium citrate (SSC) at an average concentration of 165 μg/ml on CMT-GAPS™ II (γ-aminopropylsilane) coated slides (Corning Inc., Corning, N.Y.), using a Bio-Rad VersArray MicroArrayer (Hercules, Calif.). The cDNAs were UV-cross-linked at 120 mJ/cm2 using UV Stratalinker® 2400 from Stratagene (La Jolla, Calif.). The microarrays were baked at 80° C. for 4 h. The slides were treated with succinic anhydride and N-methyl-2-pyrrolidinone to remove excess amines.


Oligonucleotide Microarrays


The Human Genome Array Ready Oligo Set Version 3.0 Set from Operon Biotechnologies (Huntsville, Ala.) includes 34,580 oligonucleotide probes representing 24,650 genes and 37,123 RNA transcripts from the human genome. The oligonucleotide targets were deposited in 3× saline sodium citrate (SSC) at an average concentration of 165 μg/ml onto CMT-GAPS II aminopropylsilane-coated slides (Corning, Corning, N.Y.) using a VersArray Microarrayer. Microarrays were UV-crosslinked at 120 mJ/cm2 using UV Stratalinker® 2400. Then slides were baked at 80° C. for 4 hours, and were treated with succinic anhydride and N-methyl-2-pyrrolidinone to remove excess amines on the slide surface. Slides were stored in boxes with slide racks and the boxes were kept in desiccators.


Real Time QPCR


Quantitative real time PCR arrays of one hundred genes associated with inflammation, transcription factors, and antigen preparation and presentation pathways were carried out using Dendritic & Antigen Presenting Cell Pathway (PAHS 406) and NFkB Pathway (PAHS 25) RT2 Profiler™ PCR Arrays (SABiosciences, Frederick, Md.) according to manufacturer's instructions. Four replicates of RNA samples isolated using PAXgene™ from Trainees before and after Training were assayed. The data were analyzed using ABiosciences' web-based software.


Reverse transcriptase reagent (iScript) and real time PCR master mix (QuantiTect™ SYBR® Green PCR Kit) were obtained from BioRad Inc., CA and QIAGEN Inc., Valencia, Calif., respectively. Real time polymerase chain reactions (PCR) were carried out in i-Cycler Real-time PCR apparatus (BioRad Inc, Milpitas, Calif.), using three to five biological replicates for each primer pair (based on sample availability). The custom oligonucleotide primers were designed using Primer3 software, or based on those from UniSTS and Universal Probe Library for Human (Roche Applied Science). Their specificities were verified in the BLAST domain at NCBI. Parallel amplification reaction using 18S rRNA primers was carried out as a control. Threshold cycle (Ct) for every run was recorded and then converted to fold change using the equation: [(1+E)ΔCt]GOI/[(1+E)ΔCt]HKG, where ΔCt stands for the difference between Ct of control and treated samples of a given gene, which is either gene of interest (GOI) or housekeeping genes (HKG), and E stands for primer efficiency, calculated from slope of best fitting standard curve of each primer pair.


ELISA


Plasma concentrations of prolactin (PRL), insulin-like growth factors I and II (IGF-I & II), tumor necrosis factor alpha (TNFα), and enzymatic activity of superoxide dismutase were determined using ELISA kits from Calbiotech, Inc. (Spring Valley, Calif., Catalog #PR063F), Diagnostic Systems Laboratories, Inc. (Webster, Tex., Catalog #s DSL-10-2800 and DSL-10-2600), Quantikine® of R&D Systems, Inc. (Minneapolis, Minn., Catalog #DTA00C) and Dojindo Molecular Technologies, Inc (Gaithersburg, Md., Catalog #S311), respectively, following manufacturers' protocols.


Microarray Data Analyses


Background and foreground pixels of the fluorescence intensity of each spot on the microarrays were segmented using ImaGene (BioDiscovery Inc., El Segundo, Calif.) and the spots with the highest 20% of the background and the lowest 20% of the signal were discarded. Local background correction was applied. Genes that passed this filter in all experiments were selected for further study. Then, sub-grid based Lowes normalization was performed for each chip independently. Additional per spot (dividing by control channel) and per gene (to specific samples) normalization were also performed under the Genespring GX platform (Agilent Technologies Inc, Santa Clara, Calif.). Statistical analysis was computed using Welch's t-test (p<0.05) with Benjamini and Hochberg False Discovery Rate (FDR) Multiple Correction to select the genes with high altered expression (for cDNA microarray data, but oligonucleotide microarray data were analyzed without FDR Correction). Two-dimensional clustering was carried out based on samples and genes for visualization and assessment of reproducibility in the profile of the significant genes across biological replicates.


Interaction Networks and Gene Ontology Enrichment


Bingo 2.3 was used for gene ontology enrichment with hypergeometric distribution with FDR (false discover rate) or Bonferroni corrections (p<0.05). Biological processes, molecular functions, and cellular components of each cluster of genes were compared to the global annotations and over-represented categories after corrections were analyzed and visualized. Functional analysis and pathways associated with stress and pathogen-regulated genes were analyzed using Ingenuity Pathway Analysis (Ingenuity Systems Inc.; Redwood City, Calif.). Cytoscape Version 2.6.1 was used for visualizing and analyzing enriched gene ontologies, and molecular interaction network constructions.


MicroRNA Analysis


Expression profiles of MicroRNAs were assayed using Agilent's human miRNA v3 microarray (Agilent Technologies Inc) consisting of 15 k targets representing 961 microRNAs. Differentially expressed microRNAs were analyzed using Qlucore Omices Explorer 2.2 (Qlucore AB) and GeneSpring GX 11.5 (Agilent Technologies Inc.). Target transcripts of profiled microRNAs were identified using target scan of Genespring, and Ingenuity Pathway Analysis (IPA) (Ingenuity Systems Inc.). Interaction networks of differentially expressed microRNAs and their target mRNAs were constructed using IPA.


Treatment of Leukocytes with Staphylococcal Enterotoxin B (SEB)


Leukocytes isolated from leucopack blood samples were plated in six well tissue culture plates (˜106 cells/ml in RPMI 1640 and 10% human AB serum) and treated with SEB (Toxin Technology Inc., Sarasota, Fla.) at a final concentration of 100 ng/ml SEB. Cells were incubated for 6 h at 37° C. and 5% CO2. At the end of the incubation period, treated leukocytes were collected by centrifugation at 350×g for 15 minutes. Cell pellets were treated with 2 ml TRIzol™ and kept at −80° C. for RNA isolation.


cDNA Microarray (Expression) Data Based Prediction of Transcription Factors, Regulatory Binding Sites and Downstream Target Identification


Potential regulatory sites of differentially regulated genes were identified using HumanGenome9999 (Agilent Technologies Inc., CA) containing partial human genome sequences (9999 bp upstream region for 21787 genes). Statistically significant (p<0.05) common regulatory motifs of 5 to 12 nucleotides long were identified. The searching region was set to range 1 to 500 nucleotides upstream of transcription start sites. Other tools used for this purpose include MATCH and TFSEARCH. Cognate transcription factors of identified (common regulatory) sites were searched from different prediction and repository databases: DBD, JASPAR, TRANSFAC® 7.0—Public using ChipMAPPER20, ConTra, Pscan and Ingenuity Pathway Analysis (IPA, ingenuity inc). Expression databased prediction Z-scores and regulatory targets were analyzed using IPA. Regulator-target interaction networks and pathways were generated using Cytoscape (Cytoscape.org) and IPA.









TABLE 3A







Transcripts that have passed Welch's T-TEST (& Bonferroni correction at q <


0.01), and selected from battlefield-like condition that have Normalized Data values


greater or less than those in baseline condition by a factor of 3 fold (59 transcripts)














Fold





ID
q-value
change
Symbol
UniGene
Description















AU119825
0.000726
3.29
A2M
Hs.212838
Alpha-2-macroglobulin


BE889785
0.00932
−3.28
ACSL1
Hs.406678
Acyl-CoA synthetase long-chain family







member 1


AL558086
0.000818
9.06
ALB
Hs.418167
Albumin


NM_001150
1.86E−05
−5.52
ANPEP
Hs.1239
Alanyl (membrane) aminopeptidase







(aminopeptidase N, aminopeptidase M,







microsomal aminopeptidase, CD13,







p150) [up-regulated in late adenovirus







type-12 infection (Journal of Virology







2005, 79: 4, 2404)]


BG541130
0.000667
−3.52
ANXA1
Hs.494173
Annexin A1


NM_020980
5.62E−05
−8.06
AQP9
Hs.104624
Aquaporin 9 [Dehydration/osmotic







adaptation in yeast (JBC 2005; 280: 8,







7186); specialized leukocyte functions







such as immunological response and







bactericidal activity (PUBMED)]


BF432072
0.00212
−3.68
ATP2B1
Hs.506276
ATPase, Ca++ transporting, plasma







membrane 1


AV710740
4.47E−07
−3.91
B2M
Hs.534255
Beta-2-microglobulin


NM_012342
0.00103
3.36
BAMBI
Hs.533336
BMP and activin membrane-bound







inhibitor homolog (Xenopus laevis)


AI348005
0.00671
−3.42
BTG1L
Hs.710041
Similar to B-cell translocation gene 1,


XM_008651
4.30E−07
−16.98
CCR7

chemokine (C-C motif) receptor 7







[suppression lead to impaired







lymphocyte migration, delayed adaptive







immune response (cell 1999), CCR7 is







key mediator in balancing immunity and







tolerance, abnormalities contribute to







immune dysregulation (clinical and







experimental immunology, 2009)]


AL549182
0.00137
−3.46
CD14
Hs.163867
CD14 molecule


M24915
0.000223
−4.9
CD44
Hs.502328
CD44 molecule (Indian blood group)


BG333618
0.00854
−12.3
CD74
Hs.436568
CD74 molecule, major







histocompatibility complex, class II







invariant chain


L26165
0.00869
−3.8
CDKN1A
Hs.370771
Cyclin-dependent kinase inhibitor 1A







(p21, Cip1)


NM_005196
0.00289
3.08
CENPF

synonyms: CENF, PRO1779;







centromere protein F (400 kD);







centromere protein F (350/400 kD,







mitosin); CENP-F kinetochore protein;







AH antigen; cell-cycle-dependent 350K







nuclear protein; Homo sapiens







centromere protein F, 350/400ka







(mitosin) (CENPF), mRNA.


AL570594
5.07E−05
4.15
COL6A1
Hs.474053
Collagen, type VI, alpha 1


BE252062
0.000478
−3.92
CORO1A
Hs.474053
Coronin, actin binding protein, 1A


NM_005211
6.28E−06
−3.25
CSF1R
Hs.586219
Colony stimulating factor 1 receptor,







formerly McDonough feline sarcoma







viral (v-fms) oncogene homolog


AU118073
0.00469
−4.52
CSPG2/
Hs.643801
Chondroitin sulfate proteoglycan 2





VCAN

(versican)


BG491425
0.000933
−15.22
CXCL1
Hs.789
Chemokine (C-X-C motif) ligand 1







(melanoma growth stimulating activity,







alpha) [involved in neurophil







recruitment (Shock 35: 6, 604)]


NM_005366
0.000153
−3.34
MAGEA11
Hs.670252
Melanoma antigen family A, 11


AL583593
0.0035
−7.3
FCN1
Hs.440898
Ficolin (collagen/fibrinogen domain







containing) 1 [expressed at the cell







surface of monocytes and granulocytes







and its receptor is found at activated but







not resting T lympohcytes (journal of







leukocyte biology 2010; 88; 1: 145); it







is part of the innate immune system and







function as recognition molecules in the







complement system (Journal of innate







immunity 2010; 2: 1, 3)]


NM_013409
0.002
3.01
FST
Hs.9914
Follistatin


Z97989
0.00897
−3.82
FYN

FYN oncogene related to SRC, FGR, YES


NM_001472
9.99E−06
3.82
GAGE7
Hs.460641
G antigen 7


AL551154
0.000131
−6.99
HCLS1
Hs.14601
Hematopoietic cell-specific Lyn







substrate 1 [induces G-CSF-Triggered







Granulopoiesis Via LEF-1 Transcription







Factor (blood 2010 114: 22, 229);







mutation defects at HCLS1 with







Kostmann disease, recombinant human







granulocyte colony-stimulating factor







(G-CSF), the prognosis and quality of







life improved dramatically (European







Journal of Pediatrics 2010, 169: 6, 659)]


BG327758
0.00021
−15.13
HLA-B
Hs.77961
Major histocompatibility complex, class







I, B


BE168491
0.00123
−7.63
HLA-C
Hs.654404
Major histocompatibility complex, class







I, C


AW407113
2.66E−05
−5.29
IGKV@,
Hs.660766
Immunoglobulin kappa variable group


AV759427
0.000205
−6.8
HLA-DPA1
Hs.347270
Major histocompatibility complex, class







II, DP alpha 1


BF795929
0.00253
−8.33
HLA-DRA
Hs.520048
Major histocompatibility complex, class







II, DR alpha


M20503
0.000575
−11.82
HLA-DRB1/
Hs.696211/
Major histocompatibility complex, class





HLA-DRB5

II, DR beta 1/5


BF974114
0.00046
−5.24
HLA-DRB1
Hs.696211
Major histocompatibility complex, class







II, DR beta 1


BF732822
0.000358
−4.98
HLA-DRB1
Hs.696211
Major histocompatibility complex, class







II, DR beta 1


AW411300
0.00267
4.36
IGF2
Hs.272259
Insulin-like growth factor 2







(somatomedin A)


AL542262
0.00121
5.48
IGFBP1
Hs.642938
Insulin-like growth factor binding







protein 1


AI634950
9.18E−07
−11.82
IGHG1
Hs.510635
Immunoglobulin heavy constant gamma







1 (G1m marker)


AA490743
0.001
−4.61
IGHG1
Hs.510635
Immunoglobulin heavy constant gamma







1 (G1m marker)


NM_000575
0.00594
−5.15
IL1A
Hs.1722
Interleukin 1, alpha


W38319
6.35E−06
−6.29
IL1B
Hs.126256
Interleukin 1, beta


AU122160
0.000811
−4.17
LAIR1
Hs.572535
Leukocyte-associated immunoglobulin-







like receptor 1


NM_006762
5.04E−07
−16.13
LAPTM5
Hs.371021
Lysosomal associated multispanning







membrane protein 5 [negative regulation







of cell surface BCR levels and B cell







activation (The Journal of Immunology,







2010, 185: 294-301); LAPTM5







negatively regulated surface TCR







expression by specifically interacting







with the invariant signal-transducing







CD3 zeta chain and promoting its







degradation without affecting other CD3







proteins, CD3 epsilon, CD3 delta, or







CD3 gamma (IMMUNITY 29: 1







Pages: 33-43)]


BF035921
0.000407
−4.65
LCP1
Hs.381099
Lymphocyte cytosolic protein 1 (L-







plastin)


NM_024318
0.000838
−3.65
LILRA6
Hs.688335
Leukocyte immunoglobulin-like







receptor, subfamily A (with TM







domain), member 6


AL560682
0.00115
−8.2
IG heavy
Hs.703938
Immunoglobulin Heavy Chain Variable





chain/

region





LOC652128


NM_004811
0.0021
−4.12
LPXN
Hs.125474
Leupaxin


BF792356
1.21E−05
4.04
MAGEA6
Hs.441113
Melanoma antigen family A, 6


AW966037
0.000159
3.1
MDK
Hs.82045
Midkine (neurite growth-promoting







factor 2)


BE742106
9.14E−06
−4.03
MGAT1
Hs.519818
Mannosyl (alpha-1,3-)-glycoprotein







beta-1,2-N-







acetylglucosaminyltransferase


NM_002473
0.00506
−3.39
MYH9
Hs.474751
Myosin, heavy chain 9, non-muscle


AU142621
0.00726
−4.46
PNP
Hs.75514
Nucleoside phosphorylase


XM_007374
0.00795
−3.25
PRKCH

protein kinase C, eta


BE266904
7.79E−05
−4.15
SATB1
Hs.517717
Special AT-rich sequence binding







protein 1 (binds to nuclear







matrix/scaffold-associating DNA's)


AL550163
0.00157
−28.25
SERPINB2
Hs.594481
Serpin peptidase inhibitor, clade B







(ovalbumin), member 2 [upregulated







under different inflammatory conditions,







null mice showed increased TH1







response, secreted by macrophages,







hemotpoeitic and nonhematopoeitic cells]


BG035651
0.00108
−10.34
SOD2
Hs.487046
Superoxide dismutase 2, mitochondrial







[Conditional loss of SOD2 led to







increased superoxide, apoptosis, and







developmental defects in the T cell







population, resulting in







immunodeficiency and susceptibility to







the influenza A virus H1N1 (Free







radical biology and medicine, 201;







50: 3, 448); manipuation of SOD2







affects drosophila survival under stress







(PLoS One 2011; 6: 5, e19866)]


AL548113
4.31E−05
−3.28
ST14
Hs.504315
Suppression of tumorigenicity 14 (colon







carcinoma)


D86980
3.55E−07
−3.57
TTC9
Hs.79170
Tetratricopeptide repeat domain 9


NM_003387
2.52E−05
−4.05
WIPF1
Hs.128067
WAS/WASL interacting protein family,







member 1
















TABLE 3B







Top 59 of stress specific genes ranked in order:
















Gene
Gene

Dengue



Yersinia




Rank
Accession
Name
Control
Virus
SEB
Stress

Pestis

Description


















1
XM_008651
CCR7
0.0943
0
0
−0.2854
0
chemokine (C-C










motif) receptor 7


2
AI634950
IGHG1
0.1285
0
0
−0.2723
0
Immunoglobulin










heavy constant










gamma 1 (G1m










marker)


3
AU118073
CSPG2
0
0
0
−0.2638
0.0673
Chondroitin










sulfate










proteoglycan 2


4
NM_006762
LAPTM5
0.1751
0
0
−0.2592
0
Lysosomal










associated










multispanning










membrane protein 5


5
NM_005211
CSF1R
0
0
0
−0.2147
0
Colony










stimulating factor










1 receptor,


6
AL558086
ALB
−0.0559
0
0
0.2136
0
Albumin


7
AW407113
HLA-C
0
0
0
−0.2119
0
Major










histocompatibility










complex, class I, C


8
BF795929
HLA-DRA
0
0
0
−0.193
0
Major










histocompatibility










complex, class II,










DR alpha


9
AV759427
HLA-DPA1
0
0
0
−0.1885
0
Major










histocompatibility










complex, class II,










DP alpha 1


10
AL549182
CD14
0
0
0
−0.187
0.0541
CD14 molecule


11
AL560682
LOC652128
0
0
0
−0.183
0
Similar to Ig










heavy chain V-II










region ARH-77










precursor


12
BE742106
MGAT1
0
0
0
−0.1764
0
Mannosyl (alpha-










1,3-)-glycoprotein










beta-1,2-N-










acetylglucosaminyl










transferase


13
AL551154
HCLS1
0.0306
0
0
−0.1738
0
Hematopoietic










cell-specific Lyn










substrate 1


14
NM_001150
ANPEP
0.0331
0
0
−0.1713
0
Alanyl










(membrane)










aminopeptidase










(aminopeptidase










N, aminopeptidase










M, microsomal










aminopeptidase,










CD13, p150)


15
W38319
IL1B
0.0424
0
0
−0.1624
0
Interleukin 1, beta


16
BG327758
IL1B
0.0702
0
0
−0.1618
0
Major










histocompatibility










complex, class I, B


17
BE266904
SATB1
0
0
0
−0.1566
0
Special AT-rich










sequence binding










protein 1 (binds to










nuclear










matrix/scaffold-










associating










DNA's)


18
BF035921
LCP1
0
0
0
−0.1546
0
Lymphocyte










cytosolic protein 1










(L-plastin)


19
NM_020980
AQP9
0.0815
0
0
−0.1491
0
Aquaporin 9


20
M20503
HLA-DRB1
0.0071
0
0
−0.147
0
Major










histocompatibility










complex, class II,










DR beta 1


21
AU142621
NP
0
0
0
−0.1463
0
Nucleoside










phosphorylase


22
AA334424
AFP
0
0
0
0.1439
0
Alpha-fetoprotein


23
NM_001946
DUSP6
0
0
0
−0.1433
0.0044
Dual specificity










phosphatase 6


24
AV710740
B2M
0.0427
0
0
−0.1403
0
Beta-2-










microglobulin


25
XM_003507
SCYB5
0
0
0
−0.1371
0
small inducible










cytokine










subfamily B (Cys-










X-Cys),


26
AL583593
FCN1
0.0203
0
0
−0.1359
0
Ficolin










(collagen/fibrinogen










domain










containing) 1


27
BE878314
FTH1
0
0
0
−0.1346
0
Ferritin, heavy










polypeptide 1


28
BF732822
HLA-DRB1
0
0
0
−0.1318
0
Major










histocompatibility










complex, class II,










DR beta 1


29
XM_003506
PPBP
0
0
0
−0.1312
0
pro-platelet basic










protein (includes










platelet basic


30
J04162
FCGR3A
0
0
0
−0.1308
0.0905
Fc fragment of










IgG, low affinity










IIIa, receptor










(CD16a)


31
AA490743
IGHG1
0
0
0
−0.1254
0
Immunoglobulin










heavy constant










gamma 1 (G1m










marker)


32
AL542262
IGFBP1
0
0
0
0.1214
0
Insulin-like










growth factor










binding protein 1


33
NM_003387
WIPF1
0
0
0
−0.1193
0
WAS/WASL










interacting protein










family, member 1


34
BF792356
MAGEA6
−0.0079
0
0
0.1181
0
Melanoma antigen










family A, 6


35
NM_004811
LPXN
0
0
0
−0.1162
0
Leupaxin


36
BG491425
CXCL1
0
0
0
−0.1138
0
Chemokine (C—X—C










motif) ligand 1


37
NM_001472
GAGE2
−0.0189
0
0
0.1127
0
G antigen 2


38
L26165
CDKN1A
0
0
0
−0.1121
0
Cyclin-dependent










kinase inhibitor










1A (p21, Cip1)


39
NM_000569
FCGR3A
0
0
0
−0.1107
0
Fc fragment of










IgG, low affinity










IIIa, receptor










(CD16a)


40
D86980
TTC9
0.0306
0
0
−0.0992
0
Tetratricopeptide










repeat domain 9


41
Z97989
FYN
0
0
0
−0.0989
0
FYN oncogene










related to SRC,










FGR, YES


42
AL550163
SERPINB2
0.1069
0
0
−0.0971
0
Serpin peptidase










inhibitor, clade B










(ovalbumin),










member 2


43
NM_005196
CENPF
0
0
0
0.095
0

Homo sapiens











centromere










protein F,










350/400ka










(mitosin)










(CENPF), mRNA.


44
NM_004987
LIMS1
0
0
0
−0.0887
0
LIM and










senescent cell










antigen-like










domains 1


45
AW966037
MDK
0
0
0
0.0877
0
Midkine (neurite










growth-promoting










factor 2)


46
AX025098
AX025098
0
0
0
−0.0871
0
unnamed protein










product; Sequence










22 from Patent










WO0031532.


47
AU119825
A2M
0
0
0
0.0867
0
Alpha-2-










macroglobulin


48
BG333618
CD74
0
0
0
−0.0847
0
CD74 molecule,










major










histocompatibility










complex, class II










invariant chain


49
N32077
IER3
0
0
0
−0.082
0
Immediate early










response 3


50
BE168491
HLA-B
0.0089
0
0
−0.0816
0
Major










histocompatibility










complex, class I, B


51
BG481840
ACTB
0
0
0
−0.0773
0
Actin, beta


52
BG541130
ANXA1
0
0
0
−0.074
0
Annexin A1


53
AU122160
LAIR1
0.0158
0
0
−0.0709
0
Leukocyte-










associated










immunoglobulin-










like receptor 1


54
M24915
CD44
0.0216
0
0
−0.0704
0
CD44 molecule


55
AL570594
COL6A1
0
0
0
0.0678
0
Collagen, type VI,










alpha 1


56
XM_007374
PRKCH
0
0
0
−0.0676
0
protein kinase C,










eta


57
AA583143
MAFB
0
0
0
−0.0638
0
V-maf










musculoaponeurotic










fibrosarcoma










oncogene










homolog B


58
XM_008466
EVI2A
0
0
0
−0.063
0
ecotropic viral










integration site 2A


59
AA309971
LAT
0
0
0
−0.0619
0
Linker for










activation of T










cells
















TABLE 4







After 8 weeks: Transcripts profiled using quantitative


real time QPCR arrays (116 transcripts were down-


regulated, and 3 transcripts were up-regulated)











Symbol
Fold
StdevRTPCR















IKBKG
−12.6188
0.339657363



RELB
−12.2737
0.284777655



IRAK1
−9.2375
0.360943649



HGDC
−6.8685
0.390462704



JUN
−5.9484
0.27944997



TNFSF14
−4.7158
0.433281621



RELA
−3.9724
0.63019443



CD40
−3.7974
0.189280078



FADD
−3.6364
0.367498363



PPM1A
−3.5988
0.27174874



INHBA
−3.5247
0.104573154



CSF1R
−3.1821
0.758689626



CXCL10
−3.1766
0.277406814



AKT1
−3.1059
0.367849974



TNFRSF1A
−2.9079
0.687128349



ACTB
−2.8481
0.351350801



TRADD
−2.8432
0.506924503



TLR9
−2.8382
0.289278965



TNFRSF10B
−2.8284
0.267218757



LTBR
−2.5847
0.570855834



CXCL1
−2.5403
0.579529817



FCER2
−2.5184
0.414730623



SLC44A2
−2.4967
−0.822611762



HMOX1
−2.4368
0.155559063



CCL4
−2.4116
0.533964145



CD209
−2.4074
0.197647764



IKBKE
−2.3784
0.555233712



ICAM1
−2.3335
0.437161543



HLA-A
−2.3295
1.214034504



ELK1
−2.3254
0.269089688



CCL3L1
−2.2462
0.27090657



TNFAIP3
−2.2346
0.389174835



TLR6
−2.2191
0.872877926



HLA-DOA
−2.2153
0.607988424



MAP3K1
−2.2115
0.61339209



IKBKB
−2.1962
0.538167096



NFKBIA
−2.1772
0.152911234



F2R
−2.1473
0.243094984



CDKN1A
−2.1287
0.707160113



CFB
−2.1287
0.164433367



CD28
−2.114
0.214883087



IL16
−2.0958
−6.38481053



ERBB2
−2.0777
0.192737356



IRAK2
−2.0669
0.234239489



CD1D
−2.035
0.200278319



TLR2
−2.0279
−2.201882954



CCL8
−2.0139
0.148872434



CD4
−2
0.616064291



HLA-DMA
−1.9793
1.430015754



FASLG
−1.9725
0.132549302



CCL11
−1.9252
0.137200432



CCL13
−1.9252
0.137200432



CCL16
−1.9252
0.137200432



CCL7
−1.9252
0.137200432



CXCL12
−1.9252
0.137200432



CXCL2
−1.9252
0.137200432



FCAR
−1.9252
0.137200432



IL2
−1.9252
0.137200432



MDK
−1.9252
0.137200432



TNFSF11
−1.9252
0.137200432



IL12B
−1.8823
0.139095667



CD40
−1.8693
0.396668136



HLA-DPA1
−1.8693
−92.22884305



RELB
−1.8661
0.207774407



REL
−1.8628
0.585844588



TLR1
−1.8628
0.602086965



CD2
−1.8468
0.857944585



ICAM1
−1.8182
0.63392797



TAPBP
−1.8119
0.419814619



RELA
−1.7932
0.273669806



CASP8
−1.7777
0.21122336



IL1R1
−1.7685
0.524613114



TICAM2
−1.7623
0.216623278



CD1B
−1.7381
0.132080179



CEBPA
−1.7112
0.784622441



CASP1
−1.7082
0.934618998



STAT1
−1.7082
0.964130752



TLR4
−1.7082
0.580800815



RAF1
−1.7023
1.180672752



CCR2
−1.6935
0.305351506



IFIT3
−1.6615
0.677571172



TNFRSF10A
−1.6615
0.230520538



IFNGR1
−1.6558
1.492757528



ITGB2
−1.6558
21.10639135



LYN
−1.6558
230.7481187



CCL19
−1.6358
0.131657942



CCL5
−1.6217
1.745561311



RAC1
−1.5938
0.515059945



MALT1
−1.5883
0.281116286



CCL3
−1.5692
0.165855825



CD80
−1.5665
0.132742476



TAP2
−1.5502
0.393041048



ACTB
−1.5369
0.382445363



IL8
−1.5157
0.483025481



CCL2
−1.5105
0.134605272



TLR3
−1.5
0.165275956



IL12A
−1.4974
0.198792804



FCGR1A
−1.4923
0.878361699



NFKB2
−1.4923
0.403365512



EDARADD
−1.4794
0.143070569



NOD1
−1.4768
0.308099861



TRAP1
−1.4439
0.483257919



NLRP12
−1.4439
0.363870333



PDIA3
−1.434
0.406179958



IL8
−1.4216
0.354085621



HLA-DQA1
−1.4167
1.178062108



MIF
−1.402
1.497615941



RPL13A
−1.3899
1.4788335



ITGAM
−1.3779
0.600004582



ATF1
−1.3519
0.183064879



CDC42
−1.3496
3.310458234



ICAM2
−1.3426
0.973584543



CCR5
−1.3333
0.145884175



CD44
−1.3036
1.754787134



IL8RA
−1.3013
1.145515093



RIPK1
−1.3013
0.462210307



CCR3
1.402
0.384641887



TLR8
1.7471
2.50546893



TLR7
1.7654
0.64730932

















TABLE 5





Average fold change: Stress-Regulated Genes Involved in Immune System


Processes, oxidative stress response and steroid biosythesis.


Functions were enriched using hypergeometric statistical analysis along


with Bonferroni correction (p < 0.05). The significance level and fold


change for each gene (obtained from microarray statistical analysis) are


shown in the last two columns respectively.



















Gene ID
Name
Description
fold
p-value










T-cell activation











AW950965
CD3E
CD3e, epsilon (CD3-
−1.5
9.80E−03




TCR complex)


BG333618
CD74
CD74, MHC, class II
−12.3
2.90E−05




invariant chain


AA309971
LAT
Linker for activation
−2.9
3.10E−04




of T cells


NM_000887
ITGAX
Integrin, alpha X
−1.4
2.10E−02




(complement




component 3




receptor 4 subunit)


NM_001767
CD2
CD2 molecule
−1.3
3.40E−02


AA766638
PAG1
Phosphoprotein
−1.5
3.10E−02




associated with




glycosphingolipid




microdomains 1


XM_001772
LCK
lymphocyte-specific
−2
1.50E−04




protein tyrosine




kinase


NM_000616
CD4
CD4 molecule
−2.3
1.00E−03


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_002838
PTPRC
Protein tyrosine
−3.2
2.50E−03


BG391140
CSK
C-src tyrosine kinase
−1.5
5.00E−03


XM_006041
CD5
CD5 antigen (p56-62)
−2.6
3.10E−04


M12824
CD8A
CD8a molecule
−3.9
1.20E−04


BC001257
GLMN
Glomulin, FKBP
−1.5
1.80E−02




associated protein


AA310902
CD3D
CD3d molecule,
−2.1
2.90E−03




delta (CD3-TCR




complex)


AI803460
CCND3
Cyclin D3
−1.5
8.80E−03


AC002310
ITGAL
integrin, alpha L
−1.4
7.30E−02




(antigen CD11A




(P180), lymphocyte




function-associated




antigen1; alpha




polypeptide)


NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase


NM_000632
ITGAM
Integrin, alpha M
−2.3
6.10E−04




(complement




component 3




receptor 3 subunit)


U81504
AP3B1
Adaptor-related
−1.6
1.00E−02




protein complex 3,




beta 1 subunit


AW780437
PRKCQ
Protein kinase C,
−1.7
9.10E−03




theta


AL136450
BCORL1
BCL6 co-repressor-
−1.7
3.90E−04




like 1


NM_004931
CD8B
CD8b molecule
−1.5
2.50E−03







B cell activation











XM_003106
PRKCD
protein kinase C,
−1.9
8.80E−04




delta


AU118181
KLF6
Kruppel-like factor 6
−2.6
3.70E−04


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_001250
CD40
CD40 molecule,
−1.4
1.80E−02




TNF receptor




superfamily member


L26165
CDKN1A
Cyclin-dependent
−3.8
2.90E−05




kinase inhibitor 1A




(p21, Cip1)


NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase


NM_002838
PTPRC
Protein tyrosine
−3.2
2.50E−03




phosphatase,




receptor type, C







Natural killer cell activation











NM_001767
CD2
CD2 molecule
−1.3
3.40E−02


AI948861
SLAMF7
SLAM family
−1.7
2.50E−02




member 7


AF285436
KIR3DL1
Killer cell
−1.8
3.90E−04




immunoglobulin-like




receptor, three




domains, long




cytoplasmic tail, 1


AL136450
BCORL1
BCL6 co-repressor-
−1.7
3.90E−04




like 1







Myeloid dendritic cell activation











NM_001767
CD2
CD2 molecule
−1.3
3.40E−02


NM_006509
RELB
V-rel
−1.9
1.30E−04




reticuloendotheliosis




viral oncogene




homolog B, nuclear




factor of kappa light




polypeptide gene




enhancer in B-cells 3




(avian)







Mast cell activation











AA309971
LAT
Linker for activation
−2.9
3.10E−04




of T cells


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)


NM_005565
LCP2
Lymphocyte
−2.5
9.30E−04




cytosolic protein 2




(SH2 domain




containing leukocyte




protein of 76 kDa)


NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase







Macrophage activation











BG333618
CD74
CD74; MHC, class
−12.3
2.90E−05




II invariant chain


AI937452
CD93
CD93 molecule
−1.6
5.60E−04


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)







Platelete activation











AI739539
PF4
Platelet factor 4
−3.3
1.10E−04




(chemokine (C-X-C




motif) ligand 4)


NM_001250
CD40
CD40 molecule,
−1.4
1.80E−02




TNF receptor




superfamily member







T-cell differentiation











BG333618
CD74
CD74; MHC, class
−12.3
2.90E−05




II invariant chain


AW950965
CD3E
CD3e; epsilon
−1.5
9.80E−03




(CD3-TCR complex)


M12824
CD8A
CD8a molecule
−3.9
1.20E−04


NM_001767
CD2
CD2 molecule
−1.3
3.40E−02


AA310902
CD3D
CD3d; delta (CD3-
−2.1
2.90E−03




TCR complex)


XM_001772
LCK
lymphocyte-specific
−2
1.50E−04




protein tyrosine




kinase


NM_000616
CD4
CD4 molecule
−2.3
1.00E−03


NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase


U81504
AP3B1
Adaptor-related
−1.6
1.00E−02




protein complex 3,




beta 1 subunit


NM_002838
PTPRC
Protein tyrosine
−3.2
2.50E−03




phosphatase,




receptor type, C







B cell differentiation











AU118181
KLF6
Kruppel-like factor 6
−2.6
3.70E−04


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase







NK T cell differentiation











U81504
AP3B1
Adaptor-related
−1.6
1.00E−02




protein complex 3,




beta 1 subunit







Monocyte differentiation











BG434340
IFI16
Interferon, gamma-
−1.7
2.70E−03




inducible protein 16


NM_002473
MYH9
Myosin, heavy chain
−3.4
2.00E−05




9, non-muscle







Myeloid cell differentiation











AA777633
MYST3
MYST histone
−1.6
3.30E−03




acetyltransferase




(monocytic




leukemia) 3


AL551154
HCLS1
Hematopoietic cell-
−7
2.20E−06




specific Lyn




substrate 1


AI739539
PF4
Platelet factor 4
−3.3
1.10E−04




(chemokine (C-X-C




motif) ligand 4)


Y14768
TNFA
TNF-alpha
−1.3
9.90E−03


BG108304
LYN
V-yes-1 Yamaguchi
−3.2
4.50E−05




sarcoma viral related




oncogene homolog


XM_008993
SPIB
Spi-B transcription
−1.5
1.40E−03




factor (Spi-1/PU.1




related)


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


AA583143
MAFB
V-maf
−2.7
1.00E−04




musculoaponeurotic




fibrosarcoma




oncogene homolog




B (avian)


NM_006509
RELB
V-rel
−1.9
1.30E−04




reticuloendotheliosis




viral oncogene




homolog B, nuclear




factor of kappa light




polypeptide gene




enhancer in B-cells 3




(avian)


AA253017
MYST1
MYST histone
−1.5
5.70E−02




acetyltransferase 1







T cell proliferation











AW950965
CD3E
CD3e molecule,
−1.5
9.80E−03




epsilon (CD3-TCR




complex)


NM_000887
ITGAX
Integrin, alpha X
−1.4
2.10E−02




(complement




component 3




receptor 4 subunit)


BC001257
GLMN
Glomulin, FKBP
−1.5
1.80E−02




associated protein


AI803460
CCND3
Cyclin D3
−1.5
8.80E−03


AC002310
ITGAL
integrin, alpha 1
−1.4
7.30E−02




(antigen CD11A




(P180), lymphocyte




function-associated




antigen 1; alpha




polypeptide)


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase


NM_000632
ITGAM
Integrin, alpha M
−2.3
6.10E−04




(complement




component 3




receptor 3 subunit)


NM_002838
PTPRC
Protein tyrosine
−3.2
2.50E−03




phosphatase,




receptor type, C


AW780437
PRKCQ
Protein kinase C,
−1.7
9.10E−03




theta


AL136450
BCORL1
BCL6 co-repressor-
−1.7
3.90E−04




like 1







B cell proliferation











XM_003106
PRKCD
protein kinase C,
−1.9
8.80E−04




delta


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_001250
CD40
CD40 molecule,
−1.4
1.80E−02




TNF receptor




superfamily member


L26165
CDKN1A
Cyclin-dependent
−3.8
2.90E−05




kinase inhibitor 1A




(p21, Cip1)


NM_002838
PTPRC
Protein tyrosine
−3.2
2.50E−03




phosphatase,




receptor type, C







activated T cell proliferation











NM_000887
ITGAX
Integrin, alpha X
−1.4
2.10E−02




(complement




component 3




receptor 4 subunit)


AC002310
ITGAL
integrin, alpha 1
−1.4
7.30E−02




(antigen CD11A




(P180), lymphocyte




function-associated




antigen 1; alpha




polypeptide)


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_000632
ITGAM
Integrin, alpha M
−2.3
6.10E−04




(complement




component 3




receptor 3 subunit)







NK cell proliferation











AL136450
BCORL1
BCL6 co-repressor-
−1.7
3.90E−04




like 1







microbial pattern recognition and binding











AI739539
PF4
Platelet factor 4
−3.3
1.10E−04




(CXCL4)


AI097512
CHIT1
Chitinase 1
−1.5
2.00E−02




(chitotriosidase)


NM_003264
TLR2
Toll-like receptor 2
−2.6
1.00E−03


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)


XM_012649
SCYA7
Small inducible
−1.5
2.80E−02




cytokine A7




(monocyte




chemotactic


AL549182
CD14
CD14 molecule
−3.5
8.20E−06


NM_002620
PF4V1
Platelet factor 4
−2.7
1.90E−03




variant 1


AA188236
CLP1
CLP1, cleavage and
−1.5
1.60E−02




polyadenylation




factor I subunit,




homolog




(S. cerevisiae)


AI087056
TICAM1
Toll-like receptor
−1.5
3.30E−03




adaptor molecule 1


AF054013
FPRL1
Formyl peptide
−1.9
2.40E−03




receptor-like 1


L10820
FPR1
Human N-formyl
−1.8
3.10E−05




peptide receptor







antigen processing and presentation











BG333618
CD74
CD74; MHC, class
−12.3
2.90E−05




II invariant chain


BF795929
HLA-DRA
MHC, class II, DR
−8.3
1.20E−05




alpha


U83582
HLA-DQB1
MHC, class II, DQ
−2
5.20E−05




beta 1


AI634950
IGHG1
Ig heavy constant
−11.8
6.20E−08




gamma1 (G1m




marker)


AL571972
FCGRT
Fc fragment of IgG,
−1.6
5.10E−02




receptor, transporter,




alpha


AV759427
HLA-DPA1
MHC, class II, DP
−6.8
2.70E−06




alpha 1


M83664
HLA-DPB1
MHC, class II, DP
−2.8
6.30E−06




beta 1


AL561631
IFI30
Interferon, gamma-
−2.6
2.80E−03




inducible protein 30


NM_006674
MICA
MHC class I
−2.2
2.50E−03




polypeptide-related




sequence A


BG327758
HLA-B
MHC, class I, B

2.70E−06


AF071019
HLA-G
HLA-G
−2.4
2.60E−06




histocompatibility




antigen, class I, G


BF663123
IGHA1
Ig heavy constant
−2.5
2.80E−03




alpha 1


AW407113
HLA-C
MHC, class I, C
−5.3
6.50E−07


BG176768
HLA-DOB
MHC, class II, DO
−2.4
1.60E−04




beta


NM_006509
RELB
Nuclear factor of
−1.9
1.30E−04




kappa light




polypeptide gene




enhancer in B-cells 3


M20503
HLA-DRB1
MHC, class II, DR
−11.8
5.30E−06




beta 1


U81504
AP3B1
Adaptor-related
−1.6
1.00E−02




protein complex 3,




beta 1 subunit


AV710740
B2M
Beta-2-
−3.9
4.30E−08




microglobulin







cytokine activity











XM_003506
PPBP
pro-platelet basic
−4.1
8.10E−05




protein (includes




platelet basic


AI739539
PF4
Platelet factor 4
−3.3
1.10E−04




(chemokine (C-X-C




motif) ligand 4)


Y14768
TNFA
TNF-alpha
−1.3
9.90E−03


XM_003507
SCYB5
Small inducible
−5.2
4.90E−05




cytokine subfamily




B (Cys-X-Cys),


XM_005349
TNFSF8
tumor necrosis factor
−1.9
1.50E−03




(ligand) superfamily,




member 8


W38319
IL1B
Interleukin 1, beta
−6.3
2.70E−07


NM_002988
CCL18
Chemokine (C-C
−1.6
1.20E−03




motif) ligand 18




(pulmonary and




activation-regulated)


AV717082
IL8
Interleukin 8

3.20E−04


BG108304
LYN
V-yes-1 Yamaguchi
−3.2
4.50E−05




sarcoma viral related




oncogene homolog


XM_012649
SCYA7
small inducible
−1.5
2.80E−02




cytokine A7




(monocyte




chemotactic


NM_000589
IL4
Interleukin 4
−1.6
6.60E−02


NM_000575
IL1A
Interleukin 1, alpha
−5.2
2.30E−05


XM_003508
GRO3
GRO3 oncogene
−1.5
2.10E−02


AA569974
CCL5
Chemokine (C-C
−1.6
4.30E−03




motif) ligand 5


NM_005408
CCL13
Chemokine (C-C
−1.6
1.90E−02




motif) ligand 13


BG288796
IL1RN
Interleukin 1
−3.6
3.90E−04




receptor antagonist


AW188005
LTB
Lymphotoxin beta
−3.2
1.00E−03




(TNF superfamily,




member 3)


BC001257
GLMN
Glomulin, FKBP
−1.5
1.80E−02




associated protein


AW965098
CCL20
Chemokine (C-C
−1.5
4.30E−03




motif) ligand 20


BG393056
PRL
Prolactin
−1.5
1.40E−02


BG491425
CXCL1
Chemokine (C-X-C
−15.2
6.90E−06




motif) ligand 1




(melanoma growth




stimulating activity,




alpha)


NM_002620
PF4V1
Platelet factor 4
−2.7
1.90E−03




variant 1







cytokine binding (receptors)











AF009962
CCR-5
CC-chemokine
−1.5
1.00E−02




receptor (CCR-5)


NM_000877
IL1R1
Interleukin 1
−1.5
3.40E−02




receptor, type I


NM_000418
IL4R
Interleukin 4
−1.6
9.40E−03




receptor


XM_008651
CCR7
Chemokine (C-C
−17
4.30E−08




motif) receptor 7


NM_001558
IL10RA
Interleukin 10
−1.6
1.20E−02




receptor, alpha


NM_000878
IL2RB
Interleukin 2
−2.7
6.30E−06




receptor, beta


AF012629
TNFRSF10C
Tumor necrosis
−1.7
2.30E−03




factor receptor




superfamily,




member 10c, decoy




without an




intracellular domain


XM_001743
TNFRSF1B
Tumor necrosis
−2.4
1.80E−03




factor receptor




superfamily,




member 1B


BC001281
TNFRSF10B
Tumor necrosis
−1.5
3.60E−03




factor receptor




superfamily,




member 10b


NM_001250
CD40
CD40 molecule,
−1.4
1.80E−02




TNF receptor




superfamily member


AL050337
IFNGR1
interferon gamma
−1.6
6.20E−03




receptor 1


AL550285
IFNGR2
Interferon gamma
−1.8
6.50E−03




receptor 2




(interferon gamma




transducer 1)







IL-12 biosynthesis











NM_003998
NFKB1
Nuclear factor of
−3.7
5.20E−05




kappa light




polypeptide gene




enhancer in B-cells




1 (p105)


NM_002198
IRF1
Interferon regulatory
−2.2
4.50E−04




factor 1


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)







IL-6 biosynthesis











W39546
CEBPB
CCAAT/enhancer
−1.9
5.30E−03




binding protein




(C/EBP), beta


W38319
IL1B
Interleukin 1, beta
−6.3
2.70E−07


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)







IL-2 biosynthesis











BC001257
GLMN
Glomulin, FKBP
−1.5
1.80E−02




associated protein


NM_000616
CD4
CD4 molecule
−2.3
1.00E−03


AW780437
PRKCQ
Protein kinase C,
−1.7
9.10E−03




theta







IL-3 biosynthesis











NM_003177
SYK
Spleen tyrosine
−1.8
7.60E−03




kinase







IL-1 biosynthesis











AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4) gene,







inflammatory response











AL570708
CD180
CD180 molecule
−1.3
1.50E−02


AL549182
CD14
CD14 molecule
−3.5
8.20E−06


U08198
C8G
Human complement
−1.5
4.00E−03




C8 gamma subunit




precursor (C8G)




gene, complete cds.


NM_003264
TLR2
Toll-like receptor 2
−2.6
1.00E−03


XM_006848
KRT1
keratin 1
−2
1.70E−03




(epidermolytic




hyperkeratosis)


NM_001250
CD40
CD40 molecule,
−1.4
1.80E−02




TNF receptor




superfamily member


NM_004029
IRF7
Interferon regulatory
−2.2
5.60E−04




factor 7


W39546
CEBPB
CCAAT/enhancer
−1.9
5.30E−03




binding protein




(C/EBP), beta


X04011
CYBB
Cytochrome b-245,
−1.6
3.20E−03




beta polypeptide




(chronic




granulomatous




disease)


AF177765
TLR4
toll-like receptor 4
−1.8
9.60E−03




(TLR4)


AI090294
CD97
CD97 molecule
−1.7
1.90E−04


NM_003998
NFKB1
Nuclear factor of
−3.7
5.20E−05




kappa light




polypeptide gene




enhancer in B-cells




1 (p105)


NM_000211
ITGB2
Integrin, beta 2
−2.2
6.30E−06




(complement




component 3




receptor 3 and 4




subunit)


AC002310
ITGAL
integrin, alpha 1
−1.4
7.30E−02




(antigen CD11A




(P180), lymphocyte




function-associated




antigen 1; alpha




polypeptide)














ID
Name
Description
Fold
P-value










Cholesterol and other steroids biosynthesis











AL558223
ACBD3
Acyl-Coenzyme A
1.6
4.10E−03




binding domain




containing 3


BE253839
DHCR24
24-
2.1
1.60E−02




dehydrocholesterol




reductase


AW271546
HSD17B1
Hydroxysteroid (17-
1.6
2.50E−03




beta) dehydrogenase 1


AF078850
HSD17B12
Hydroxysteroid (17-
1.4
1.70E−02




beta) dehydrogenase 12


AK001889
PRLR
Prolactin receptor
1.9
5.00E−03


NM_000786
CYP51A1
Cytochrome P450,
1.9
3.90E−04




family 51, subfamily




A, polypeptide 1


NM_004110
FDXR
Ferredoxin reductase
1.8
5.00E−03


NM_000103
CYP19A1
Cytochrome P450,
1.9
1.60E−02




family 19, subfamily




A, polypeptide 1


BE378962
DHCR7
7-dehydrocholesterol
1.8
2.60E−03




reductase


J05158
CPN2
Carboxypeptidase N,
1.9
2.10E−03




polypeptide 2, 83 kD


AL521605
OPRS1
Opioid receptor,
2.2
4.70E−04




sigma 1


AW117731
HMGCS1
3-hydroxy-3-
2.2
2.00E−03




methylglutaryl-




Coenzyme A




synthase 1 (soluble)


BG324529
MVD
Mevalonate
2.3
5.20E−03




(diphospho)




decarboxylase







Ergosterol biosynthesis











AL521605
OPRS1
Opioid receptor,
2.2
4.70E−04




sigma 1







Dopamine biosynthesis











AW156890
SNCA
Synuclein, alpha
1.5
1.20E−02




(non A4 component




of amyloid




precursor)







Fatty acid biosynthesis











AL359403
MCAT
Malonyl CoA: ACP
1.6
5.40E−03




acyltransferase




(mitochondrial)


AF097514
SCD
Stearoyl-CoA
5.2
4.40E−04




desaturase (delta-9-




desaturase)







transcription Transcription factors











BE266904
SATB1
Special AT-rich
−4.2
1.70E−06




sequence binding




protein 1


NM_006763
BTG2
BTG family,
−3.8
7.70E−04




member 2


NM_003998
NFKB1
NFk light
−3.7
7.00E−05




polypeptide gene




enhancer in B-cells




1 (p105)


AI348005
BTG1
B-cell translocation
−3.4
3.70E−05




gene 1, anti-




proliferative


NM_006060
IKZF1
IKAROS family zinc
−2.6
7.00E−05




finger 1 (Ikaros)


AL555297
SF1
Splicing factor 1
−2.4
1.70E−06


NM_014795
ZFHX1B
Zinc finger
−2.3
6.10E−04




homeobox 1b


AL561046
TSC22D3
TSC22 domain
−2.2
5.00E−04




family, member 3


NM_002198
IRF1
Interferon regulatory
−2.2
5.00E−04




factor 1


NM_004029
IRF7
Interferon regulatory
−2.2
5.80E−04




factor 7


AV708340
UBA52
Ubiquitin A-52
−2.1
6.80E−04




residue ribosomal




protein fusion




product 1


AI631717
HNF4A
Hepatocyte nuclear
2
3.90E−03




factor 4, alpha


BG529476
HMGB2
High-mobility group
2.1
2.50E−03




box 2


BG340581
SREBF2
Sterol regulatory
2.3
1.50E−03




element binding




transcription factor 2


AL525810
FOXM1
Forkhead box M1
2.3
2.40E−04


M95585
HLF
Hepatic leukemia
2.4
5.00E−04




factor


NM_003220
TFAP2A
Transcription factor
2.4
2.00E−03




AP-2 alpha


AL575644
NFKBIL1
NFk light
3.3
4.60E−03




polypeptide




enhancer in B-cells




inhibitor-like 1







Ssuperoxide metabolism











BG035651
SOD2
Superoxide
−10.3
1.20E−07




dismutase 2,




mitochondrial


BG421245
CYBA
Cytochrome b-245,
−2.1
1.00E−06




alpha polypeptide


XM_002200
NCF2
neutrophil cytosolic
−2
2.90E−04




factor 2 (65 kD,




chronic







heat Heat shock proteins











BG327949
HSP90B1
Heat shock protein
1.6
4.50E−02




90 kDa beta (Grp94),




member 1


AB007877
HSPA12A
Heat shock 70 kDa
1.7
2.10E−03




protein 12A


BE742483
HSPA4
Heat shock 70 kDa
1.9
1.00E−05




protein 4


AI640615
BAG4
BCL2-associated
1.9
1.10E−03




athanogene 4


BG032173
HSPD1
Heat shock 60 kDa
2.5
5.90E−04




protein 1




(chaperonin)









Example 1

The biomarker findings are presented which were identified from gene expression changes in leukocytes collected from (informed and consented) US Army Ranger Cadets who underwent eight-weeks of Army Ranger Training (RASP, Ranger Assessment and Selection Program). Our subjects were exposed to extreme physical and psychological stressors of Ranger Training, which is designed to emulate extreme battlefield scenarios such as strenuous physical activity, sleep deprivation, calorie restriction, and survival emotional stresses—pushing cadets to their physical and psychological limits. Though these men were among the best of the best, many trainees dropped out in the first phase of the three-phased RASP Training. The Army Ranger population provides a rare opportunity to study extreme stress, and to contribute to the understanding of intense chronic stress in general. Particularly, the ability to collect pre-training samples for comparison with post-training samples is rarely practical in any other chronically and extremely stressed patients.


Our studies focus in identifying molecular mediators of compromised protective immunity caused by social and battlefield-like stresses, and in identifying pathogen-induced biomarkers under severe stress background. Social and physiological stresses, particularly, which are frequent or chronic are major contributors of stress-induced immune dysfunction. In this study, we employed experimental and computational approaches to identify molecules and signaling pathways involved in the host's response towards battlefield-like stress, and in assessing protective immunity status of the stressed host towards infection.


In the first approach, we used genome-wide transcriptome, and microRNA profiling and in-vitro pathogen exposure of leukocytes (isolated from Army Ranger Trainees) to identify stress-suppressed transcripts and pathways critical in protective immune response. We have identified a number of stress response biomarkers (transcripts and pathways) that have potential implication in compromising the immune function. The most compromised pathways include antigen preparation and presentation, and T-cell activation pathways. Suppressed immune response genes remained suppressed even after ex-vivo exposure of post-RASP leukocytes to the mitogenic toxin, Staphylococcal enterotoxin B (SEB). On the other hand, complete and differential counts of post-training WBCs were within normal ranges. This impaired activation is an indicator of anergy, and compromised protective immunity.


Example 2

In the second approach, we used rigorous computational analyses in identifying up-stream regulatory modules (and molecular networks) of stress-suppressed genes. We identified up-stream regulators of differentially altered transcripts, which include immune related and steroid hormone inducible transcription factors, stress response factors, and microRNAs. Some stress induced microRNAs, and a number of stress-inhibited transcription factors were found to regulate or be modulated by many compromised immune response transcripts.


The identification of exceptionally enriched suppression of antigen presentation and lymphocyte activation pathways (in spite of normal blood cell counts) are remarkable since these findings are consistent with prior observations of poor vaccine responses, impaired wound healing and infection susceptibility associated with chronic intense stress.


Some of the transcripts were unique to RASP stressors (severe and chronic stress), even in the presence of other pathogens, to which we briefly refer in this manuscript. These specific transcripts may have potential use as diagnostic markers to distinguish debilitating chronic stress from that of infection.


CONCLUSION

The subject matter of the present invention (biomarkers) solves the drawbacks of other routinely used assays that check the status of the immune system process. Many clinical laboratories do differential and complete white blood cell counting to ascertain integrity of the immune system. Some advanced clinical laboratories do challenge assays (proliferation assays) to check the viability of immune cells (in addition to cell counting). In our case, even though the cells are within their normal ranges (cell counting would have indicated normal), we still see no measurable response to SEB challenge (and we have the molecular indicators of the why). Our molecular markers can be used to check the protective or compromised nature of the immune system regardless of whether the cells are anergic (within normal range in terms of their numbers but not protective) or otherwise.


DEFINITIONS

Welch's t-test: Statistical comparative analysis whereby the means and variance of compared groups are not assumed to be the equal.


Transcriptome: Genome-wide transcripts of human or any other living thing.


Transcript: Messenger RNA (ribonucleic acid) or any other small RNA molecule.


Pathway: regulatory hierarchy of bio-molecules (proteins, transcripts, or metabolites) forming a specific biological process (function).


Normal Control: A person or sample from a person, or genes or transcripts from a person, or expression profile from a person or persons that has not been subjected to stress.


Diagnostic biomarkers: stress effected genes, transcripts, cDNAs, mRNA, miRNAs, rRNA, tRNA, peptides and proteins.


**Gene names and accession numbers presented herein are standard gene names and accession numbers for genes that are found in the NCBI GenBank®. GenBank® is the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences (Nucleic Acids Research, 2013 January; 41(D1):D36-42). GenBank is part of the International Nucleotide Sequence Database Collaboration, which comprises the DNA DataBank of Japan (DDBJ), the European Molecular Biology Laboratory (EMBL), and GenBank at NCBI. These three organizations exchange data on a daily basis.


REFERENCES



  • 1. Cohen S, Janicki-Deverts D & Miller G E. Psychological stress and disease. JAMA 2007; 298(14): 1685-1687.

  • 2. Rokutan K, Morita K, Masuda K, Tominaga K, Shikishima M, Teshima-Kondo S et al. Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J Med Invest 2005; 52(3-4): 137-144.

  • 3. Motoyama K, Nakai Y, Miyashita T, Fukui Y, Morita M, Sanmiya K et al. Isolation stress for 30 days alters hepatic gene expression profiles, especially with reference to lipid metabolism in mice. Physiol Genomics 2009; 37(2): 79-87.

  • 4. Zhang Y, Miao J, Hanley G, Stuart C, Sun X, Chen T et al. Chronic restraint stress promotes immune suppression through toll-like receptor 4-mediated phosphoinositide 3-kinase signaling. J Neuroimmunol 2008; 204(1-2): 13-19.

  • 5. Padgett D A & Glaser R. How stress influences the immune response. Trends in Immunology 2003; 24(8): 444-448.

  • 6. Kiecolt-Glaser J K, Glaser R, Gravenstein S, Malarkey W B & Sheridan J. Chronic stress alters the immune response to influenza virus vaccine in older adults. Pro Nat Acad Sci (USA) 1996; 93(7): 3043-3047.

  • 7. Tournier J N, Mathieu J, Mailfert Y, Multon E, Drouet C, Jouan A et al. Chronic restraint stress induces severe disruption of the T-cell specific response to tetanus toxin vaccine. Immunology 2001; 102(1): 87-93.

  • 8. Li J, Cowden L G, King J D, Briles D A, Schroeder H W, Stevens A B et al. Effects of chronic stress and interleukin-10 gene polymorphisms on antibody response to tetanus vaccine in family caregivers of patients with Alzheimer's disease. Psychosom Med 2007; 69(6): 551-559.

  • 9. Glaser R, Sheridan J, Malarkey W B, MacCallum R C & Kiecolt-Glaser J K. Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. Psychosom Med 2000; 62(6): 804-807.

  • 10. Kiank C, Holtfreter B, Starke A, Mundt A, Wilke C & Schutt C. Stress susceptibility predicts the severity of immune depression and the failure to combat bacterial infections in chronically stressed mice. Brain Behav Immun 2006; 20(4): 359-368.

  • 11. Reiche E M, Nunes S O & Morimoto H K. Stress, depression, the immune system, and cancer. Lancet Oncol 2004; 5(10): 617-625.

  • 12. Friedl K E, Moore R J, Hoyt R W, Marchitelli L J, Martinez-Lopez L E & Askew E W. Endocrine markers of semistarvation in healthy lean men in a multistressor environment. J Appl Physiol 2000; 88(5): 1820-1830.

  • 13. Nindl B C, Barnes B R, Alemany J A, Frykman P N, Shippee R L & Friedl K E. Physiological consequences of U.S. Army Ranger training. Med Sci Sports Exerc 2007; 39(8): 1380-1387.

  • 14. Mendis C, Das R, Hammamieh R, Royaee A, Yang D, Peel S et al. Transcriptional response signature of human lymphoid cells to staphylococcal enterotoxin B. Genes Immun 2005; 6(2): 84-94.

  • 15. Paik I H, Toh K Y, Lee C, Kim J J & Lee S J. Psychological stress may induce increased humoral and decreased cellular immunity. Behav Med 2000; 26(3): 139-141.

  • 16. Glaser R, MacCallum R C, Laskowski B F, Malarkey W B, Sheridan J F & Kiecolt-Glaser J K. Evidence for a shift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. J Gerontol Ser A-Biol Sci Med Sci 2001; 56(8): M477-M482.

  • 17. O'Connell R M, Kahn D, Gibson W S, Round J L, Scholz R L, Chaudhuri A A et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity; 33(4): 607-619.

  • 18. Kurowska-Stolarska M, Alivernini S, Ballantine L E, Asquith D L, Millar N L, Gilchrist D S et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA; 108(27): 11193-11198.

  • 19. Das R, Hammamieh R, Neill R, Ludwig G V, Eker S, Lincoln P et al. Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells. BMC Infect Dis 2008; 8: 104.

  • 20. Marinescu V D, Kohane, I. S., and Riva, A. (2005). The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. In: Nucleic Acids Res pp D91-97.

  • 21. Christin C, Hoefsloot H C, Smilde A K, Hoekman B, Suits F, Bischoff R et al. A critical assessment of feature selection methods for biomarker discovery in clinical proteomics. Mol Cell Proteomics; 12(1): 263-276.

  • 22. Wang S & Zhu J. Improved centroids estimation for the nearest shrunken centroid classifier. Bioinformatics 2007; 23(8): 972-979.

  • 23. Tibshirani R, Hastie T, Narasimhan B & Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99(10): 6567-6572.

  • 24. Sharma P, Sahni N S, Tibshirani R, Skaane P, Urdal P, Berghagen H et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 2005; 7(5): R634-644.

  • 25. Shankavaram U T, Reinhold W C, Nishizuka S, Major S, Morita D, Chary K K et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007; 6(3): 820-832.

  • 26. Selaru F M, Wang S, Yin J, Schulmann K, Xu Y, Mori Y et al. Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. Bioinform Biol Insights 2007; 1: 127-136.

  • 27. Suarez-Farinas M, Shah K R, Haider A S, Krueger J G & Lowes M A. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatol; 10:1.


Claims
  • 1. A method for detecting a subset of messenger RNA (mRNA) in a subject method comprising: (a) obtaining a sample from the subject, wherein the sample comprises whole blood;(b) isolating total RNA from the sample, wherein the total RNA comprises a subset of messenger RNA (mRNA);(c) determining the level of a subset of mRNA in the sample, wherein the subset of mRNA consists of CCR7, IGHG1, CSPG2, LAPTM5, CSF1R, ALB, HLA-C, HLA-DRA, HLA-DPA1, CD14, LOC652128, MGAT1, HCLS1, ANPEP, IL1B, SATB1, LCP1, AQP9, and HLA-DRB1.
  • 2. The method of claim 1, wherein leukocytes are isolated from the whole blood sample.
  • 3. The method of claim 1, wherein the method further comprises producing cDNA from the isolated mRNA.
  • 4. The method of claim 1, wherein the method further comprises detecting the subset set of mRNA using a microarray.
  • 5. The method of claim 4, wherein the microarray is a cDNA microarray.
Parent Case Info

This application claims priority and is a continuation application of PCT application no. PCT/US2013/000097 filed Mar. 28, 2013, pending, which claims priority of U.S. provisional application No. 61/687,731 filed Apr. 28, 2012.

GOVERNMENT INTEREST

The invention described herein may be manufactured, used and licensed by or for the U.S. Government.

US Referenced Citations (1)
Number Name Date Kind
20120094859 Redei Apr 2012 A1
Non-Patent Literature Citations (37)
Entry
Muhie (2007) “Host Gene Expression Responses to Dengue, Plague and Staphylococcus Enterotoxin B in the Presence and Absence of Severe Physiological Stress” dissertation, Georgetown University, ISBN 9780549939672 http://pqdtopen.proquest.com/pubnum/3339919.html.
Shippee et al. (1994) Nutritional and Immunological Assessment of Ranger Students with Increased Caloric Intake. No. USARIEM-T95-5. Army Research Inst of Environmental Medicine Natick MA.
Hughes et al. (2001) “DNA microarrays for expression profiling” Current Opinion in Chemical Biology 5(1):21-25.
Yoo et al. (J. Microbiol. Biotechnol., 2008, 19(7):635-646) (Year: 2008).
Statnikov et al. (Bioinformatics, 2005, 21(5):631-643) (Year: 2005).
George-Gay et al. (Journal of PeriAnesthesia Nursing, 2003, 18(2):96-117) (Year: 2003).
Kanno et al. (BMC Genomics, 2006, 7(64):1-14) (Year: 2006).
Lyons et al. (BMC Genomics, 2007, 8:64, doi:10.1186/1471-2164-8-64) (Year: 2007).
Affymetrix (GeneChip® Human Genome U133 Plus 2.0 Array datasheet, 2004) (Year: 2004).
Invitrogen (Handbook for Dynabeads® and mRNA DirectTM Micro Kit, 2007) (Year: 2007).
Cohen, et al., Psychological stress and disease. JAMA 2007;298(14):1685-1687.
Rokutan, et al., Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response.,J Med Invest 2005; 52(3-4):137-144.
Motoyama et al., Isolation stress for 30 days alters hepatic gene expression profiles, especially w/ reference to lipid metabolism in mice, Physiol Genomics 2009; 37(2):79-87.
Zhang et al., Chronic restrain stress promotes immune suppression through toll-like receptor 4-mediated phosphoinositide 3-kinase signaling, J Neuroimmunol 2008;204(1-2);13-19.
Padgett, et al., Haw stress influences ths immune response; Trends in Immunology 2003;24(8),444-448.
Kiecolt-Glaser, et al., Chronic stress alters the immune response to influenza virus vaccine in older adults; Pro Nat Acad Sci (USA) 1996;93(7);3043-3047.
Tournier, et al., Chronic restraint stress induces severe disruption of the T-cell 3 specific response to tetanus toxin vaccine, immunology 2001;102(1);87-93.
Li, et al., Effects of chronic stress and interleukin-10 gene polymorphisms on antibody response to tetanus vaccine . . . , Psychosom Med 2007;69(6): 551-559.
Glaser, et al., Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine, Psychosom Med 2000; 62(6): 804-807.
Kiank, et al., Stress susceptibility predicts the severity of immune depression and the failure to combat bacterial infection . . . ; Brain Behav Immun 20(4):359-368, (2006).
Reiche, e tal., Stress, depression, the immune system, and cancer; Lancet Oncol 2004; 5(10):617-625.
Freidl, et al., Endocrine markers of semistravation in healthy lean men in a multistressor environment; J Appl Physiol 2000; 88(5): 1820-1830.
Nindl, et al.,Physiological consequences of U.S. Army Ranger training; Med Sci Sprots Exerc 2007; 39(8): 1380-1387.
Mendis, et al, Transcriptional response signature of human lymphoid cells to staphylococcal enterotoxin B. Genes Immun 2005; 6(2):84-94.
Paik, et al., Psychological stress may induce increased humoral and decreased cellular immunity; Behav Med 2000; 26(3): 139-141.
Glaser, et al., Evidence for a shift in the Th-1 to Th-2 cytokine response asociated w/ chronic stess and aging; J Gerontol ser A-Biol Sci Med Sci 2001; 56(8); M477-M482.
O'Connell, et al., MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development; Immunity; 33(4): 607-619, (2010).
Kurowska-Stolarska, et al., MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis; Proc Natl Acad Sci USA; 108(27): 11193-11198, (2011).
Das, et al., Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells; BMC Infect Dis 2008; 8: 104.
Marinescu, et al., The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. In: Nucleic Acids Res pp. D91-D97, (2005).
Christin, et al., A critical assessment of feature selection methods for biomarker discovery in clinical proteomics; Mol Cell Proteomics; 12(1): 263-276, (2013).
Wang, et al., Improved centroids estimation for the nearest shrunken centroid classifier; Bioinformatics 2007; 23(8): 972-979.
Tibshirani, et al., Diagnosis of multiple cancer types by shrunken centroids of gene expression; Proc Natl Acad Sci USA 2002; 99(10): 6567-6572.
Sharma, et al., Early detection to breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 2005; 7(5): R634-644.
Shankavararn, et al, Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study; Mol Cancer Ther 2007; 6(3): 820-832.
Selaru, et al., Beyond field effect: Analysis of shrunken centroids in normal esophageal epithelia detects concomitant esophageal . . . ; Bioinform Bio Insights 2007; 1: 127-136.
Suarez-Farinas, et al., Personalized medicine in psoriasis: developing a genomic classifier to predict histological response io Alfacept; BMC Dermatol; 10: 1, (2010).
Related Publications (1)
Number Date Country
20150051094 A1 Feb 2015 US
Provisional Applications (1)
Number Date Country
61687731 Apr 2012 US
Continuations (1)
Number Date Country
Parent PCT/US2013/000097 Mar 2013 US
Child 14121808 US